{"title":"Farmaci Dermatologici: Creme, Pomate e Unguenti per la Pelle","description":"\u003cp\u003eFarmaci per uso cutaneo in crema, pomata, unguento, gel e soluzione: cortisonici a bassa potenza, antibiotici e chemioterapici topici, antipruriginosi, cicatrizzanti e riparatori, cheratolitici per verruche e calli, trattamenti per acne e rosacea. Formulazioni da banco e con ricetta per la cura quotidiana della pelle irritata, infetta o lesa. Spedizione veloce in 24\/48 ore.\u003c\/p\u003e","products":[{"product_id":"cortidro-0-5-crema-20g","title":"Cortidro 0.5% cream 20g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product is used in case of insect bites, itching, erythema or localized burns, eczema.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of cream contains 0.5 g of Hydrocortisone acetate Excipients with known effects: cetostearyl alcohol, methyl p-hydroxybenzoate and propyl p-hydroxybenzoate For the complete list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCetostearyl alcohol, Sodium lauryl sulfate, Vaseline oil, Stringy Vaseline, methyl P-hydroxybenzoate, propyl P-hydroxybenzoate, Distilled water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. The use of hydrocortisone is contraindicated in the case of viral, bacterial or fungal diseases.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor adults and children over two years of age: apply a minimal amount of cream to the area and rub lightly to facilitate penetration. The application can be repeated two or three times a day for a few days. In case of failure to respond to therapy, it is advisable to contact your doctor. Do not exceed the recommended dose.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe cream is not used in ophthalmology nor should it be applied to the areas around the eyes. Avoid use in the treatment of vulvar itching if associated with vaginal discharge. Avoid prolonged applications, particularly on large surfaces. The use, especially if prolonged, of topical products can give rise to irritation or sensitization phenomena. In this case it is necessary to interrupt treatment and consult your doctor in order to institute suitable therapy. \u003cu\u003eVisual disturbances\u003c\/u\u003e Visual disturbances may be reported with the use of systemic and topical corticosteroids. If a patient presents with symptoms such as blurred vision or other visual disturbances, referral to an ophthalmologist should be considered for evaluation of possible causes which may include cataracts, glaucoma, or rare diseases such as central serous chorioretinopathy (CSCR), which have been reported after the use of systemic and topical corticosteroids. \u003cu\u003ePediatric population\u003c\/u\u003e In children under two years of age, the product should be administered in cases of actual need under the direct supervision of a doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt is necessary to observe caution in the association of corticosteroids with amphotericin B because they can combine their hypokalemic actions. Corticosteroids antagonize the effects of anticoagulants, therefore simultaneous use with them is not recommended, especially if they are coumarin derivatives. Barbiturates accelerate the metabolism of corticosteroids due to enzymatic induction and reduce their effect, therefore their combination is not recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSystemic side effects of corticosteroid preparations for topical use are extremely unlikely due to the low doses used: if they occur, discontinue therapy. Eye disorders, uncommon (≥1\/1,000, \u003c1\/100): Vision, blurred (see also section 4.4). \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the indicated doses, no clinically unfavorable symptoms were detected; in case of emergency the doctor intervenes according to the symptoms detected.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product should be administered in cases of actual need and under the direct supervision of a doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCortidro does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":51131255718215,"sku":"010318032","price":14.79,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-spa-cortidro-0-5-crema-20g-farmacia-dottor-tili-1213792280.jpg?v=1767143770"},{"product_id":"polaramine-1-crema-25g","title":"Polaramine 1% cream 25g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePolaramin 1% cream\u003c\/b\u003e It is indicated for the local symptomatic treatment of itchy dermatitis, sunburn and insect bites.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDeschlorpheniramine maleate 1 g \/ 100 g. Excipients: Cetyl alcohol; Lanolin ethoxylated esters; Methyl p-hydroxybenzoate. For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAllantoin, Glycerin, Sorbitol 70%, Glyceryl monostearate, Spermaceti, Cetyl alcohol, Ethoxylated lanolin esters, Methyl p-hydroxybenzoate, Liquid paraffin, Natural lavender essence, Purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eApply the cream to the affected part with a light massage to promote deep penetration, 2-3 times a day, depending on the intensity of the inflammatory symptom.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePolaramin 1% cream\u003c\/b\u003e It is not for ophthalmic use. \u003cb\u003ePolaramin 1% cream\u003c\/b\u003e it is well tolerated but its use, especially if prolonged, can give rise to sensitization phenomena, as with all topical products. In this case, suspend treatment and institute suitable therapy. Avoid application on very large areas in the presence of abrasions to avoid systemic absorption. If absorbed, it may cause excitability, especially in children. Do not apply on exuding surfaces, on live sores, on areas of skin with blisters, genital organs, mucous membranes. Exposure to the sun of the treated areas can give rise to photosensitization phenomena. Stop using \u003cb\u003ePolaramin 1% cream\u003c\/b\u003e if you experience a burning sensation or rash, or if the original condition persists or if irritation develops. Avoid occlusive dressing. The use of antihistamines should be stopped approximately 48 hours before carrying out skin tests as these medicines can prevent or reduce positive reactions. The medicine contains: - cetyl alcohol and ethoxylated esters of lanolin which can cause local skin reactions (e.g. contact dermatitis); - methyl parahydroxybenzoate which can cause allergic reactions (even delayed); - an aroma containing limonene and linalool. Limonene and linalool can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNot known.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe local application of \u003cb\u003ePolaramin 1% cream\u003c\/b\u003e it can cause burning, skin rashes and photosensitivity reactions. After topical application of antihistamines on large areas of the skin, systemic side effects have been reported. Reporting of suspected adverse reactions Reporting of suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system, https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTo date, there are no known cases of overdose due to the use of \u003cb\u003ePolaramin 1% cream\u003c\/b\u003e.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn pregnant and breastfeeding women, the product should only be used if clearly necessary and under the direct supervision of a doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNot applicable.\u003c\/p\u003e","brand":"Bayer","offers":[{"title":"Default Title","offer_id":51131265548615,"sku":"018554081","price":11.72,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/bayer-spa-polaramine-1-crema-25g-farmacia-dottor-tili-1213792281.jpg?v=1767144170"},{"product_id":"vagisil-2-crema-20g","title":"Vagisil 2% cream 20g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVulvar and perianal itching.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of cream Active ingredients: Lidocaine base 2.0 g\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePurified water, Stearic acid, Glycerin, Glycerin monostearate, Sulphonated castor oil, Triethanolamine, Diethylene glycol monoethyl ether, Isopropyl alcohol, Rose scent, Chlorothymol, Zinc oxide, Sodium dioctylsulfosuccinate.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to lidocaine, or to other components of the product and substances closely related from a chemical point of view. Pediatric age. Pregnancy and breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product is intended for use by adult patients. Apply VAGISIL cream in a thin layer on the area to be treated: the application can be repeated up to 3 or 4 times a day, if necessary. Use only for short treatment periods\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo special precautions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAs with any local anaesthetic, any reactions and complications are more easily avoided by using the minimum effective dosages. Pay attention to the elderly and seriously ill patients. Do not use in case of damage to the mucous membranes, a condition in which it is necessary to consult a doctor. The use of products for topical use, especially if prolonged, can give rise to sensitization phenomena, in which case it is necessary to interrupt the treatment and, if necessary, institute suitable therapy. After a short period of treatment, without appreciable results or in case of suspected fungal infection, consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePropanol prolongs the plasma half-life of lidocaine. Cimetidine may increase plasma levels of lidocaine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOnly extremely improper use of the product can cause unwanted systemic effects. The appearance, albeit in rare cases, of allergic reactions is possible. Patients allergic to anesthetics derived from paraminobenzoic acid (procaine, tetracaine, benzocaine, etc.) present cross-reactivity towards lidocaine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptoms of overdose are characterized by neuroexcitatory manifestations (tremors, convulsions followed by depression, respiratory failure and coma) and cardiovascular alterations with hypotension and bradycardia. Treatment is symptomatic. Any seizures can be controlled with the administration of barbiturates or short-acting benzodiazepines. The side effects reported above and the symptoms of overdose attributable to lidocaine have never occurred with the correct use of VAGISIL, respecting therapeutic indications and dosage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePreclinical studies conducted on rats and rabbits have not highlighted risks to the fetus. However, since no clinical data are available in pregnant women, the use of the product is to be considered contraindicated in this situation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNobody.\u003c\/p\u003e","brand":"Combe","offers":[{"title":"Default Title","offer_id":51131271905607,"sku":"028700033","price":12.83,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/combe-italia-srl-vagisil-2-crema-20g-farmacia-dottor-tili-1213792269.jpg?v=1767133209"},{"product_id":"foille-scottature-crema-29-5g","title":"Foille sunburn cream 29.5g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMinor burns, sunburn, skin irritations from various chemical-physical agents, insect bites. In the dressing of abrasions, abrasions and superficial skin wounds.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of cream contains: Active ingredients: benzyl alcohol 4 g; benzocaine 5 g; chloroxylenol 0.1 g. Excipients with known effects: sodium lauryl sulfate, eugenol. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHydrogenated vegetable oil, ceresin (solid paraffin), yellow beeswax, monodiglycerides (of higher fatty acids), corn oil, calcium hydrate, sodium borate, PEG 32, sodium lauryl sulfate, maleic anhydride, eugenol, sodium calcium EDTA, 8-hydroxyquinoline, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. The product is not suitable for ophthalmic use.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eApply the cream in a thin and uniform layer directly to the lesion. In case of limited lesions, it is advisable - following the application of the cream - to cover with sterile gauze. The dressing should not be removed for at least 48 hours, in order not to disturb the granulation process. In some cases the initial dressing will not have to be removed and changed even for a longer period of time, but it must be kept well moistened with FOILLE SCTATURE. It is recommended not to exceed the maximum limit of 4 applications per day, both in adults and children.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore below 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFOILLE SCOTTATURE is for external use only. Use of the product, especially if prolonged, can give rise to sensitization phenomena. The effectiveness and safety of benzocaine depend on correct dosage. Therefore, it is necessary to use the minimum quantity of product sufficient to obtain the desired effect, applying it with caution in subjects with severely damaged mucous membranes and the site of inflammatory processes that could cause excessive absorption of this active ingredient. FOILLE SBURN must only be used on small, superficial lesions of the skin and for short periods of time. Do not apply near the eyes. In the event of deep wounds, or disseminated insect bites, or serious burns, or particularly extensive mild burns, always consult your doctor before using the product. If the medical condition for which this preparation is used persists for longer, if irritation occurs, if redness, swelling or pain persists or if you have an infection, discontinue use and consult your doctor. Do not use the product in children under 6 months of age; its administration is recommended only after consulting the doctor between 6 months and 2 years of age. \u003cb\u003eFOILLE SCULDING contains sodium lauryl sulphate\u003c\/b\u003e: This medicinal product contains 60 mg of sodium lauryl sulphate per 100 g of cream equivalent to 0.6 mg\/g. Sodium lauryl sulfate may cause skin irritation (stinging or burning sensation) or intensify skin reactions caused by other medicines when applied to the same area. Patients with reduced skin barrier function e.g. following atopic dermatitis they are more sensitive to the irritating properties of sodium lauryl sulfate. \u003cb\u003eFOILLE SCOTTATURE contains eugenol\u003c\/b\u003e: This medicine contains the allergen eugenol which may cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo notes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of products for topical application, especially if prolonged, can give rise to sensitization phenomena. In this case, discontinue treatment and institute appropriate therapy. Rarely, high absorption of benzocaine can cause serious reactions (increase in methemoglobin, with the appearance of cyanosis), particularly in children and the elderly, who require prompt hospital intervention. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRare cases of an increase in methemoglobin referable to excessive absorption of benzocaine, particularly in children and the elderly, have been reported in the literature. In the event of the onset of cyanosis, contact the nearest hospital for the appropriate therapy (supportive therapy and intravenous administration of methylene blue). In case of accidental ingestion, it is advisable to implement the normal medical measures recommended in case of intoxication.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known contraindications for use in case of pregnancy or breastfeeding. However, it is advisable to consult your doctor before taking the drug during pregnancy and breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFOILLE BURN does not influence the state of vigilance; therefore, it does not alter the ability to drive or use machinery.\u003c\/p\u003e","brand":"Vemedia","offers":[{"title":"Default Title","offer_id":51131282948423,"sku":"006228062","price":10.42,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/vemedia-manufacturing-b-v-foille-scottature-crema-29-5g-farmacia-dottor-tili-1213792240.jpg?v=1767133889"},{"product_id":"duofilm-16-7-15-collodio-15ml","title":"Duofilm 16.7% + 15% collodion 15ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDUOFILM is indicated for the topical treatment of warts, corns and calluses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of collodion contain: Active ingredients: salicylic acid 16.7 g; lactic acid 15 g. \u003cu\u003eExcipients with known effects\u003c\/u\u003e: ethyl alcohol. For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe only excipient of DUOFILM is the elastic collodion BP, consisting of: rosin, castor oil and collodion, in turn consisting of pyroxylin, \u003cb\u003eethyl alcohol\u003c\/b\u003e and ether.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicine is contraindicated in patients with a previous hypersensitivity reaction to the active substances or to any of the excipients listed in paragraph 6.1. Do not use on open wounds, irritated or red skin, or any infected area. DUOFILM should not be applied to the face, anogenital area and large areas. The product should not be applied to moles, birthmarks, seborrheic warts, warts, facial or mucous membrane warts, or hairy warts surrounded by red or unusually colored edges.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eFor topical use only\u003c\/u\u003e \u003cu\u003eAdults, including the elderly \u003c\/u\u003e DUOFILM must be applied using the appropriate brush only on the affected part, avoiding the liquid coming into contact with healthy skin. DUOFILM must be applied to the wart, callus or corn once a day, preferably in the evening before going to bed, following the following instructions for use: 1. Immerse the part to be treated in hot water for about 5 minutes and dry carefully with a clean towel. 2. Pass the affected surface with a nail file, an abrasive stone, a cardboard file or a rough cloth, taking care not to cause bleeding. 3. Apply with the appropriate DUOFILM brush on the wart, callus or corn, taking care not to overflow onto the surrounding healthy skin. 4. Allow the solution to dry completely: in the case of localized forms on the feet or if the wart, callus or callus involve large areas, the area must be covered with a plaster to facilitate the absorption of the active ingredients. It is recommended to continue treatment until one of the following conditions occurs: - the corns and calluses have been treated for 2 weeks - the warts have been treated for 12 weeks - or until the wart, callus or corn is completely removed and the normal wrinkling of the skin has been restored. For warts, a clinically visible improvement should be observed in 1-2 weeks but the maximum effect is expected after 4-8 weeks. Advise the patient to consult their doctor or pharmacist if the wart persists beyond 12 weeks of treatment. Consider alternative treatment if warts cover a large area of ​​the body (more than 5 cm²) (see Special warnings and precautions for use). Advise the patient to consult their doctor or pharmacist if skin irritation develops. Due to the flammable nature of the medicine, patients should avoid smoking or going near open flames during application and immediately after use. \u003ci\u003ePediatric population\u003c\/i\u003e Do not administer under two years of age. In children between 2 and 12 years of age, the product must be administered only if clearly necessary and under direct medical supervision. Use in children must take place under the supervision of an adult. Elderly No dose adjustment is required since significant systemic exposure is not expected. Hepatic impairment No dose adjustment is required as significant systemic exposure is not expected. Renal insufficiency No dose adjustment is required since significant systemic exposure is not expected. Do not exceed the recommended doses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDue to its high flammability, it is recommended to store the product at temperatures not exceeding 25°C, away from flames and heat sources. Close the bottle tightly after use. A notable increase in density of the product indicates that the bottle has not been closed properly and that the solvent contained in it has partially evaporated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt treatment and institute appropriate therapy. Apply DUOFILM only on warts without overflowing onto the surrounding healthy skin. The medicine may cause eye irritation. Avoid contact with eyes and other mucous membranes. If the product accidentally comes into contact with mucous membranes or eyes, rinse immediately and abundantly with water, remove the collodion film that forms and continue rinsing with water for at least a quarter of an hour. Avoid application on healthy skin (see Side effects). The medicine may cause skin irritation. If unexpected skin irritation develops, treatment should be discontinued. Consider alternative treatment if warts cover a large area of ​​the body (more than 5 cm²) due to the potential toxicity of salicylates. The medicine is not recommended in diabetic patients or patients with circulatory problems or peripheral neuropathy, unless under the supervision of a doctor. Taking oral salicylates during or immediately after a viral illness has been associated with Reye's syndrome and consequently there is a theoretical risk also with topical salicylates. Therefore, the product should not be used in children or adolescents during or immediately after chickenpox, influenza or other viral infections. Salicylates have been reported to be excreted in breast milk (see Fertility, pregnancy and lactation). Patients should be advised not to inhale vapours. Accidental ingestion of keratolytics containing salicylic acid and lactic acid at high concentrations can have serious, sometimes fatal, consequences. The product must not be used to prevent the formation of warts. Do not ingest. Keep out of the sight and reach of children. This medicinal product contains 2228 mg of alcohol (ethanol) in each unit volume which is equivalent to 158 mg\/g. May cause burning sensation on damaged skin.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSalicylic acid and lactic acid topical solution may increase the absorption of other topical medications. Therefore the concomitant use of salicylic acid and lactic acid solution and other topical medicines on the treated area should be avoided. Since the systemic absorption of topical solutions of salicylic acid and lactic acid is low, interaction with systemically administered medicinal products is not expected.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following convention is used to classify the frequency of an adverse reaction and is based on the CIOMS guidelines: • very common (\u003e 1\/10), • common (\u003e 1\/100 to \u003c 1\/10), • uncommon (\u003e1\/1,000 to \u003c 1\/100), • rare (\u003e 1\/10,000 to \u003c 1\/1,000) and • very rare (\u003c 1\/10,000), • not known (frequency cannot be estimated from the available data). Data from clinical studies:\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eCommon: Skin rash.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eVery common: Application site reaction, pruritus, burning sensation, erythema, scaling, dryness.\u003c\/p\u003e\n\u003cp\u003eCommon: Skin hypertrophy.\u003c\/p\u003e\n\u003cp\u003ePost marketing data\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eRare: Application site hypersensitivity reaction including inflammation.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eRare: Application site pain and irritation, skin discolouration at the application site\/skin discolouration. Exposure of healthy skin may lead to skin exfoliation and blistering (see Special warnings and precautions for use). Allergic dermatitis.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions \u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSigns and symptoms \u003c\/u\u003e In case of accidental oral ingestion, symptoms of salicylate toxicity may occur. The risk of developing symptoms of salicylate poisoning or salicylism increases if salicylic acid and lactic acid topical solution is used in excess or for prolonged periods of time. It is therefore very important to respect the recommended duration and frequency of treatment. \u003cu\u003eTreatment \u003c\/u\u003e Overdose should be treated as clinically indicated or as recommended by the poison control center, where available. There is no specific treatment for accidental oral ingestion of lactic acid and salicylic acid solutions. In case of accidental ingestion, the patient should be treated according to local guidelines under appropriate observation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy \u003c\/u\u003e The safety of use of the salicylic acid and lactic acid solution during pregnancy has not been established. Studies in animals administered oral salicylic acid have demonstrated embryotoxicity at high doses (see Preclinical safety data). The medicine is not recommended during pregnancy. \u003cu\u003eBreastfeeding \u003c\/u\u003e Salicylates are excreted in breast milk. The medicine is not recommended during breastfeeding. If used or administered during breastfeeding, avoid contact with the breast area to prevent accidental ingestion by the infant.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo effects are expected based on the safety profile of the product.\u003c\/p\u003e","brand":"Eg","offers":[{"title":"Default Title","offer_id":51131289010503,"sku":"034522019","price":15.07,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/eg-spa-duofilm-16-7-15-collodio-15ml-farmacia-dottor-tili-1213792222.jpg?v=1767134130"},{"product_id":"zoviraxlabiale-5-crema-2g","title":"Zoviraxlabiale 5% cream 2g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eZOVIRAXLABIALE 5% cream is indicated in the treatment of herpes simplex virus infections of the lips (\u003ci\u003eherpes labialis\u003c\/i\u003e recurrent) in adults and adolescents (over 12 years of age).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne gram of cream contains: Active ingredient: Aciclovir 50 mg. Excipients with known effects: cetostearyl alcohol, sodium lauryl sulfate, propylene glycol. \u003cb\u003eFor the complete list of excipients see section 6.1.\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePoloxamer 407, \u003cb\u003eCetostearyl alcohol\u003c\/b\u003e, \u003cb\u003eSodium lauryl sulfate\u003c\/b\u003e, White Vaseline, Liquid Paraffin, Arlacel 165, Dimethicone 20, \u003cb\u003ePropylene glycol\u003c\/b\u003e, Purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance, to valaciclovir, or to any of the excipients. Children under 12 years old.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTopical use. \u003ci\u003eAdults and adolescents over 12 years of age:\u003c\/i\u003e ZOVIRAXLABIALE 5% cream must be applied 5 times a day at intervals of approximately 4 hours, omitting the night application. ZOVIRAXLABIALE 5% cream must be applied as early as possible, preferably during the earliest phases (prodromes or erythema). However, treatment can also be started in the later stages (papules or vesicles). Treatment must continue for at least 4 days. If there is no healing, treatment can continue for up to a maximum of 10 days. If the lesions are still present after 10 days, it is advisable for patients to consult their doctor. Patients should wash their hands before and after applying the cream and avoid unnecessary rubbing of the lesions or touching them with a towel in order to avoid worsening or transmission of the infection. \u003ci\u003eChildren under the age of 12\u003c\/i\u003e: The safety and efficacy of ZOVIRAXLABIALE have not been studied in patients under 12 years of age. \u003ci\u003ePatients with renal or hepatic insufficiency\u003c\/i\u003e: Aciclovir is eliminated mainly via the kidneys, but systemic absorption of aciclovir after topical application is negligible. Consequently, no dose modification is required in patients with renal or hepatic impairment (see \u003ci\u003ePharmacokinetic properties\u003c\/i\u003e).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore at a temperature not exceeding 25°C. Do not refrigerate.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eZOVIRAXLABIALE 5% cream should only be used for cold sores present on the mouth. Application to mucous membranes such as those of the mouth and eyes is not recommended and should not be used in the treatment of genital herpes. Particular care should be taken to avoid accidental application into the eyes. It is recommended that people with particularly severe forms of recurrent cold sores consult their doctor. The use of the product, especially if prolonged, can give rise to sensitization phenomena: if this happens, treatment should be stopped and the doctor should be consulted. It is recommended that those who suffer from cold sores avoid transmitting the virus, especially when active lesions are present (for example by washing their hands before and after applying the cream, see \u003ci\u003eDosage and method of administration\u003c\/i\u003e). The use of ZOVIRAXLABIALE 5% cream in immunocompromised patients is not recommended. It is recommended that such patients consult their doctor regarding the treatment of any infection. \u003cb\u003e \u003cu\u003eImportant information about some excipients:\u003c\/u\u003e \u003c\/b\u003e ZOVIRAXLABIALE 5% cream contains propylene glycol, cetostearyl alcohol, sodium lauryl sulphate. This medicinal product contains 200 mg of propylene glycol per dose equivalent to 400 mg\/g. This medicine contains cetostearyl alcohol. May cause localized skin reactions (e.g. contact dermatitis). This medicinal product contains 3.75 mg sodium lauryl sulphate per dose equivalent to 7.5 mg\/g. Sodium lauryl sulfate may cause skin irritation (stinging or burning sensation) or intensify skin reactions caused by other medicines when applied to the same area.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo clinically significant interactions have been identified.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe side effects reported for ZOVIRAXLABIALE 5% cream are listed according to the following convention on the frequency of occurrence: very common: ≥ 1\/10, common: ≥ 1\/100 and \u003c 1\/10, uncommon: ≥ 1\/1000 and \u003c 1\/100, rare: ≥ 1\/10000 and \u003c 1\/1000, very rare: \u003c1\/10000, not known (frequency cannot be estimated from the available data). \u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e. \u003cu\u003eUncommon\u003c\/u\u003e: • transient burning or pain after application of ZOVIRAXLABIALE 5% cream, • moderate dryness or flaking of the skin, • itching; \u003cu\u003eRare\u003c\/u\u003e: • erythema, • contact dermatitis following application. Where sensitivity tests were conducted, it was shown that the substances causing reactivity phenomena were the components of the base cream rather than aciclovir.\u003cb\u003eImmune system disorders\u003c\/b\u003e. \u003cu\u003eVery rare\u003c\/u\u003e: • immediate hypersensitivity including angioedema and urticaria. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eZOVIRAXLABIALE 5% cream is a preparation for topical use. Even if the entire contents of a 2 g cream pack of ZOVIRAXLABIALE 5% cream are ingested or applied topically, no undesirable effects should be expected. In case of suspected overdose, the patient should consult his doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eFertility\u003c\/b\u003e: No data are available regarding the effects of aciclovir in oral or i.v. formulation. for infusion on fertility in women. In a study of 20 male patients with normal sperm counts, aciclovir administered orally at doses of up to 1 gram per day for up to 6 months was shown to have no effect on the number, morphology and motility of sperm in men. \u003cb\u003ePregnancy\u003c\/b\u003e: You should consider using ZOVIRAXLABIALE 5% cream only if the potential benefits outweigh the possibility of unknown risks. However, the systemic exposure to aciclovir following topical application of aciclovir cream is very low. A post-marketing registry on the use of aciclovir in pregnancy provided data on pregnancy outcomes in women exposed to various formulations of aciclovir. These observations did not show an increase in the number of birth defects among subjects exposed to aciclovir compared to the general population and all birth defects did not show any particularity or common characteristics, such as to suggest a single cause. Systemic exposure to aciclovir following topical application of aciclovir cream is very low. \u003cb\u003eBreastfeeding\u003c\/b\u003e: Although some data indicate that aciclovir passes into breast milk following systemic administration, the dose that an infant receives following use of ZOVIRAXLABIALE 5% cream in the mother should be insignificant. During pregnancy and breastfeeding, ZOVIRAXLABIALE 5% cream must be used only after consulting your doctor and evaluating with him the risk\/benefit ratio in the individual case.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eZOVIRAXLABIALE 5% cream is unlikely to have any effect on the ability to drive and use machines.\u003c\/p\u003e","brand":"Haleon","offers":[{"title":"Default Title","offer_id":51131289043271,"sku":"037868015","price":9.72,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/haleon-italy-srl-zoviraxlabiale-5-crema-2g-farmacia-dottor-tili-1213792227.jpg?v=1767134111"},{"product_id":"streptosil-con-neomicina-99-5-0-5-polvere-cutanea-10g","title":"Streptosil with neomycin 99.5% + 0.5% skin powder 10g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSuperficial skin infections (folliculitis, furunculosis, small burns and infected wounds).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e10 g of powder contains: sulfathiazole 9.95 g and neomycin sulphate 0.05 g. 20 g of ointment contains: sulfathiazole 0.4 g and neomycin sulfate 0.1 g.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eskin powder: none. ointment: Vaseline oil, white Vaseline, white wax.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSTREPTOSIL with NEOMICIN is contraindicated in patients with: - Hypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. - Infections of the ear canal in case of perforation of the tympanic membrane.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSkin dust\u003c\/b\u003e Lift the colored cap, rhythmically and thoroughly press the two faces of the bottle, holding it horizontally or slightly obliquely; lightly sprinkle the affected region with the powder and cover with sterile gauze; renew the application twice a day. It is recommended to apply a light sprinkling, using the minimum amount of powder necessary to avoid the formation of crusts and allow rapid dissolution and diffusion of the components. Do not exceed the recommended doses. \u003cb\u003eOintment\u003c\/b\u003e Apply a thin layer of ointment 2-3 times a day. Do not exceed the recommended doses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo special precautions for storage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSTREPTOSIL with NEOMICIN is not for ophthalmic use; it is indicated for external use only. The application of STREPTOSIL with NEOMICIN on extensively and deeply damaged skin, such as in skin infections secondary to extensive burns and trophic ulcers, could favor the systemic absorption of its active ingredients, exposing patients to serious secondary effects, such as nephrotoxicity and ototoxicity. The medicine must not be used in ear canal infections in case of perforation of the eardrum since in these cases the topical use of neomycin can cause deafness (see section 4.3). As with other aminoglycosides, the simultaneous and\/or sequential systemic or topical administration of other nephrotoxic drugs should be avoided. \u003ci\u003eDuration of treatment\u003c\/i\u003e The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. As with other antibiotics, prolonged use of neomycin can lead to the development of resistant microorganisms, including fungi. If this occurs it is necessary to discontinue treatment and institute appropriate therapy. After a short period of treatment without appreciable results, or in case of worsening of the patient's condition, it is necessary to consider suspending treatment. \u003ci\u003e Pediatric population\u003c\/i\u003e In early childhood the product should be administered in cases of actual need, under the direct supervision of the doctor. The application of neomycin on large areas of the skin and for prolonged periods can lead to systemic absorption; this eventuality occurs more easily when occlusive bandage is used, in particular in newborns, since the diaper can act as an occlusive bandage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTopical neomycin has demonstrated cross-sensitivity with other aminoglycosides; co-administration of another aminoglycoside, especially systemically, is not recommended due to potential ototoxic and nephrotoxic effects. Topical application of sulfathiazole may result in sensitization and preclude subsequent systemic use of sulfonamides.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFollowing the use of STREPTOSIL with NEOMICIN, the side effects indicated below may occur. The frequency of these side effects is not known. \u003cu\u003eInfections and infestations\u003c\/u\u003e Bacterial and fungal superinfections. \u003cu\u003eImmune system disorders\u003c\/u\u003e Hypersensitivity reactions \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e Itching. \u003cu\u003eSystemic pathologies and conditions relating to the administration site\u003c\/u\u003e Swelling, redness. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn the event of prolonged applications on large surfaces or lesions, systemic absorption of the medicine may occur with passage of sulfathiazole and\/or neomycin into circulation. If overdose is suspected, treatment should be discontinued.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003ePregnancy \u003c\/i\u003e The safety of topical use of sulfonamides or neomycin during pregnancy has not been established. In pregnant women, the product should be administered in cases of actual need, under the direct supervision of a doctor. \u003ci\u003eBreastfeeding\u003c\/i\u003e There are no adequate studies available to evaluate the effects in women during breastfeeding and therefore to determine the risk in infants. The product should be used in breastfeeding women only if strictly necessary, under the direct supervision of a doctor. \u003ci\u003eFertility\u003c\/i\u003e No studies have been conducted to evaluate the effects on fertility in humans.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSTREPTOSIL with NEOMICIN has no or negligible influence on the ability to drive and use machines.\u003c\/p\u003e","brand":"Cheplapharm","offers":[{"title":"Default Title","offer_id":51131295760711,"sku":"023589031","price":10.23,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/cheplapharm-arzneimittel-gmbh-streptosil-con-neomicina-99-5-0-5-polvere-cutanea-10g-farmacia-dottor-tili-1213792203.jpg?v=1767134508"},{"product_id":"reactifargan-2-crema-20g","title":"Reactifargan 2% cream 20g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal symptomatic treatment for insect bites and other localized skin irritation phenomena such as redness, burning, itching and sunburn.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eActive ingredient: promethazine 2.00 g Excipients with known effects: methyl-para-hydroxybenzoate, propyl-para-hydroxybenzoate, D-limonene, geraniol, linalool and butylated hydroxytoluene. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePolyacrylamide isoparaffin laureth-7, octyl methoxycinnamate, methyl parahydroxybenzoate, propyl parahydroxybenzoate, lavender compound oil, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients. Eczema Secreting lesions. Children under 2 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e Apply 3-4 times a day. Do not exceed the recommended number of daily applications. Avoid application on very large areas of the body. \u003cu\u003eMethod of administration\u003c\/u\u003e Topical use.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore below 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProlonged and inappropriate use of the product can give rise to allergic sensitization phenomena with consequent worsening of symptoms. If this occurs, treatment should be suspended and the situation reassessed. If applied to very large areas of the skin REACTIFARGAN may cause drowsiness (see section 4.7). Given that the application of REACTIFARGAN can delay the healing process, it must not be used more than 3-4 consecutive days on lesions in which this phenomenon is taking place. In the case of sunburn, apply the product and avoid further exposure of the irritated skin to the sun. If skin rashes, irritation and burning phenomena occur, treatment should be suspended. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e REACTIFARGAN contains \u003cb\u003emethyl p-hydroxybenzoate\u003c\/b\u003e e \u003cb\u003epropyl p-hydroxybenzoate\u003c\/b\u003e which can cause allergic reactions (even delayed). REACTIFARGAN contains lavender oil, a fragrance which in turn contains D-Limonene, geraniol and linalool which can cause allergic reactions; REACTIFARGAN contains octyl methoxycinnamate which in turn contains butylated hydroxytoluene which may cause localized skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNot known.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe side effects reported below arise from post-marketing and have an unknown frequency (the frequency cannot be established from the available data).\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency not known: Dermatitis edema erythema bullous lesions photosensitivity\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo clinical data are available regarding the risk during pregnancy and breastfeeding. The administration of REACTIFARGAN during pregnancy and breast-feeding should only be considered if the expected benefit for the mother outweighs the risk for the fetus or child.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eToo abundant application of the product on very large areas of the skin can determine the absorption of the drug and cause drowsiness in particularly sensitive patients. Instruct the patient to pay particular attention before driving or using machinery.\u003c\/p\u003e","brand":"Johnson \u0026 Johnson","offers":[{"title":"Default Title","offer_id":51131364933959,"sku":"002516060","price":13.06,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/johnson-johnson-spa-reactifargan-2-crema-20g-farmacia-dottor-tili-1213791913.jpg?v=1767115768"},{"product_id":"vectavir-1-crema-2g","title":"Vectavir 1% cream 2g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVectavir is indicated for the treatment of herpes labialis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach gram of cream contains 10 mg of penciclovir. Excipients with known effects: 77.2 mg of cetostearyl alcohol, 416.8 mg of propylene glycol. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSolid paraffin, Liquid paraffin, Cetostearyl alcohol, Propylene glycol, Cetomacrogol 1000, Purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance penciclovir, to famciclovir or to any of the excipients listed in section 6.1. Children under the age of 12.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eAdults (including the elderly) and children over 12 years of age: \u003c\/i\u003e VECTAVIR should be applied at intervals of approximately 2 hours throughout the day. Treatment, to be continued for 4 days, should be started as soon as possible, at the first sign of infection. However, even in patients who start therapy later, VECTAVIR has proven effective in accelerating the healing of lesions, reducing the pain associated with them and shortening the time for viral spread. \u003cu\u003eApplication instructions\u003c\/u\u003e: VECTAVIR must be applied, in an amount suitable for the size of the area to be treated, with a clean finger or with a disposable applicator which must be discarded after use [\u003ci\u003efor packages containing applicators\u003c\/i\u003e]. \u003ci\u003ePediatric population \u003c\/i\u003e. \u003ci\u003eChildren (under 12 years of age)\u003c\/i\u003e: Vectavir is not recommended for use in children under 12 years of age due to a lack of data on safety and\/or efficacy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 30°C. Do not freeze.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe cream should only be applied to lesions on the lips and around the mouth. Application to mucous membranes (e.g. in the eyes, mouth or nose or on the genitals) is not recommended. Particular care should be taken to avoid application in or near the eyes. Severely immunocompromised patients (e.g. patients with AIDS or bone marrow transplant recipients) should be encouraged to consult a physician if oral therapy is indicated. Vectavir contains cetostearyl alcohol: it may cause local skin reactions (e.g. contact dermatitis). Vectavir contains 416 mg of propylene glycol in each gram of cream: may cause skin irritation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eExperience in clinical trials has not identified interactions resulting from the concomitant administration of drugs for topical or systemic use and Vectavir cream.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVectavir cream was well tolerated during studies in humans. Experience from clinical trials has shown that there is no difference in the frequency or type of adverse reactions between Vectavir cream and placebo. The most common events are adverse events in the application area. Adverse reactions are listed below by system organ class, class and frequency. The frequencies are defined as follows: \u003ci\u003every common\u003c\/i\u003e (\u0026gt;1\/10); \u003ci\u003ecommon\u003c\/i\u003e (\u003e1\/100 to \u003c1\/10); \u003ci\u003euncommon\u003c\/i\u003e (\u003e1\/1,000 to \u003c1\/100); \u003ci\u003erare\u003c\/i\u003e (\u003e1\/10,000 to \u003c1\/1,000); \u003ci\u003every rare\u003c\/i\u003e (\u0026lt;1\/10.000), \u003ci\u003enot known\u003c\/i\u003e (frequency cannot be estimated from the available data). Within each frequency class, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eCommon: Application site reactions (including skin burning sensation, skin pain, hypoesthesia).\u003c\/p\u003e\n\u003cp\u003ePost-marketing surveillance highlighted the following adverse events (all reactions were either localized or general). It is difficult to define a frequency for post-marketing adverse events and therefore events are listed with an unknown frequency.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders: Hypersensitivity, urticaria.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders: Allergic dermatitis (including rash, pruritus, blisters and edema).\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: http:\/\/www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEven after oral ingestion of the entire contents of a pack of VECTAVIR cream, no side effects should occur; penciclovir is poorly absorbed after oral administration. However, irritation of the oral cavity may occur. In case of accidental ingestion, no specific treatment is necessary.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e: When the cream is used in pregnant women, there is unlikely to be any cause for concern about adverse effects as systemic absorption of penciclovir following topical application of Vectavir cream was found to be minimal (see section 5.2). As the safety of penciclovir in pregnant women has not been established, Vectavir cream should be used, on the advice of a doctor, during pregnancy or by mothers who are breastfeeding, only if the potential benefits outweigh the potential risks associated with treatment. \u003cb\u003eBreastfeeding:\u003c\/b\u003e When the cream is used in women who are breastfeeding, there is unlikely to be any cause for concern about adverse effects as systemic absorption of penciclovir following topical application of Vectavir cream has been found to be minimal (see section 5.2). There is no information on the excretion of penciclovir in human milk.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVectavir does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Perrigo","offers":[{"title":"Default Title","offer_id":51131372601671,"sku":"032155018","price":13.48,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/perrigo-italia-srl-vectavir-1-crema-2g-farmacia-dottor-tili-1213791865.jpg?v=1767137608"},{"product_id":"trofodermin-5-5-30-ml-spray-cutaneo-soluzione","title":"Trofodermin 5% + 5% 30 ml cutaneous spray solution","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAbrasions and erosions; ulcerative skin lesions (variceal ulcers, bedsores, traumatic ulcers); nipple fissures, anal fissures; burns; infected wounds; healing delays; radiodermatitis; dystrophic skin conditions (dryness, cracking, flaking).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eTrofodermin 500 mg\/100 g + 500 mg\/100 g cream\u003c\/i\u003e 100 g contain: Clostebol acetate 500 mg; neomycin sulphate 500 mg. Excipients with known effects: lanolin, nipasept (methyl para-hydroxybenzoate, ethyl para-hydroxybenzoate and propyl para-hydroxybenzoate). \u003ci\u003eTrofodermin 5 mg\/ml + 5 mg\/ml cutaneous spray, suspension\u003c\/i\u003e One 30 ml pressurized container contains: Clostebol acetate 0.150 g; neomycin sulphate 0.150 g. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eTrofodermin 500 mg\/100 g + 500 mg\/100 g cream\u003c\/i\u003e Polyethylene glycol stearate; stearic acid; liquid paraffin; lanolin; dimethicone; nipasept (methyl para-hydroxybenzoate, ethyl para-hydroxybenzoate and propyl para-hydroxybenzoate); floranol; purified water. \u003ci\u003eTrofodermin 5 mg\/ml + 5 mg\/ml cutaneous spray, suspension\u003c\/i\u003e Magnesium stearate; liquid paraffin; isobutane at 3.2 bar.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eTrofodermin 500 mg\/100 g + 500 mg\/100 g cream\u003c\/i\u003e: 1–2 applications per day. Spread a thin layer of cream on the injured part and possibly cover the injured part with sterile gauze. \u003ci\u003eTrofodermin 5 mg\/ml + 5 mg\/ml cutaneous spray, suspension\u003c\/i\u003e:1–2 applications per day; If necessary, cover the injured part with sterile gauze.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eTrofodermin 500 mg\/100 g + 500 mg\/100 g cream\u003c\/i\u003e For storage conditions after first opening, see paragraph 6.3. \u003ci\u003eTrofodermin 5 mg\/ml + 5 mg\/ml cutaneous spray, suspension\u003c\/i\u003e Protect from sunlight and do not expose to temperatures above 50° C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eContinuous use of Trofodermin should be avoided. Due to the potential risk of ototoxicity and nephrotoxicity of neomycin, prolonged use of the product on large damaged surfaces that could allow the absorption of neomycin is not recommended. \u003cu\u003ePediatric population\u003c\/u\u003e Continuous use of Trofodermin should be avoided; especially in early childhood. \u003ci\u003eTrofodermin 5 mg\/ml + 5 mg\/ml cutaneous spray, suspension\u003c\/i\u003e As regards the spray, it is recommended to shake before use, not to spray on a flame or incandescent body, not to turn upside down during dispensing, not to inhale or spray into the eyes. \u003ci\u003eTrofodermin 500 mg\/100 g + 500 mg\/100 g cream\u003c\/i\u003e contains: – lanolin: can cause local skin reactions (e.g. contact dermatitis) – nipasept (methyl para-hydroxybenzoate, ethyl para-hydroxybenzoate and propyl para-hydroxybenzoate): can cause allergic reactions (even delayed).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe combined use of Trofodermin with topical preparations containing other aminoglycoside antibiotics may increase the risk of sensitization or enhance any secondary effects.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. Furthermore, prolonged application for several weeks on large areas of damaged tissue could give rise to the appearance of systemic effects, such as hypertrichosis due to massive absorption of clostebol. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe possibility of overdose can only be contemplated in the case of prolonged applications and on large areas of damaged skin, which could induce secondary effects of the type indicated above. In this case the treatment will need to be suspended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDuring pregnancy and breastfeeding, the drug should only be administered if clearly needed.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTrofodermin is not known to interfere with the ability to drive or use machinery.\u003c\/p\u003e","brand":"Sit Laboratorio Farmaceutico","offers":[{"title":"Default Title","offer_id":51730202591559,"sku":"020942049","price":12.54,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sit-laboratorio-farmac-srl-trofodermin-5-5-30-ml-spray-cutaneo-soluzione-farmacia-dottor-tili-1213791406.jpg?v=1767138167"},{"product_id":"streptosil-neomicina-2-0-5-20-g-unguento","title":"Streptosyl neomycin 2% + 0.5% 20 g ointment","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSuperficial skin infections (folliculitis, furunculosis, small burns and infected wounds).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e10 g of powder contains: sulfathiazole 9.95 g and neomycin sulfate 0.05 g. 20 g of ointment contains: sulfathiazole 0.4 g and neomycin sulfate 0.1 g.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eskin powder: none. ointment: Vaseline oil, white Vaseline, white wax.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSTREPTOSIL with NEOMICIN is contraindicated in patients with: - Hypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. - Infections of the ear canal in case of perforation of the tympanic membrane.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSkin dust\u003c\/b\u003e Lift the colored cap, rhythmically and thoroughly press the two faces of the bottle, holding it horizontally or slightly obliquely; lightly sprinkle the affected region with the powder and cover with sterile gauze; renew the application twice a day. It is recommended to apply a light sprinkling, using the minimum amount of powder necessary to avoid the formation of crusts and allow rapid dissolution and diffusion of the components. Do not exceed the recommended doses. \u003cb\u003eOintment\u003c\/b\u003e Apply a thin layer of ointment 2-3 times a day. Do not exceed the recommended doses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo special precautions for storage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSTREPTOSIL with NEOMICIN is not for ophthalmic use; it is indicated for external use only. The application of STREPTOSIL with NEOMICIN on extensively and deeply damaged skin, such as in skin infections secondary to extensive burns and trophic ulcers, could favor the systemic absorption of its active ingredients, exposing patients to serious secondary effects, such as nephrotoxicity and ototoxicity. The medicine must not be used in ear canal infections in case of perforation of the eardrum since in these cases the topical use of neomycin can cause deafness (see section 4.3). As with other aminoglycosides, the simultaneous and\/or sequential systemic or topical administration of other nephrotoxic drugs should be avoided. \u003ci\u003eDuration of treatment\u003c\/i\u003e The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. As with other antibiotics, prolonged use of neomycin can lead to the development of resistant microorganisms, including fungi. If this occurs it is necessary to discontinue treatment and institute appropriate therapy. After a short period of treatment without appreciable results, or in case of worsening of the patient's condition, it is necessary to consider suspending treatment. \u003ci\u003e Pediatric population\u003c\/i\u003e In early childhood the product should be administered in cases of actual need, under the direct supervision of the doctor. The application of neomycin on large areas of the skin and for prolonged periods can lead to systemic absorption; this eventuality occurs more easily when occlusive bandage is used, in particular in newborns, since the diaper can act as an occlusive bandage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTopical neomycin has demonstrated cross-sensitivity with other aminoglycosides; co-administration of another aminoglycoside, especially systemically, is not recommended due to potential ototoxic and nephrotoxic effects. Topical application of sulfathiazole may result in sensitization and preclude subsequent systemic use of sulfonamides.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFollowing the use of STREPTOSIL with NEOMICIN, the side effects indicated below may occur. The frequency of these side effects is not known. \u003cu\u003eInfections and infestations\u003c\/u\u003e Bacterial and fungal superinfections. \u003cu\u003eImmune system disorders\u003c\/u\u003e Hypersensitivity reactions \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e Itching. \u003cu\u003eSystemic pathologies and conditions relating to the administration site\u003c\/u\u003e Swelling, redness. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn the event of prolonged applications on large surfaces or lesions, systemic absorption of the medicine may occur with passage of sulfathiazole and\/or neomycin into circulation. If overdose is suspected, treatment should be discontinued.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003ePregnancy \u003c\/i\u003e The safety of topical use of sulfonamides or neomycin during pregnancy has not been established. In pregnant women, the product should be administered in cases of actual need, under the direct supervision of a doctor. \u003ci\u003eBreastfeeding\u003c\/i\u003e There are no adequate studies available to evaluate the effects in women during breastfeeding and therefore to determine the risk in infants. The product should be used in breastfeeding women only if strictly necessary, under the direct supervision of a doctor. \u003ci\u003eFertility\u003c\/i\u003e No studies have been conducted to evaluate the effects on fertility in humans.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSTREPTOSIL with NEOMICIN has no or negligible influence on the ability to drive and use machines.\u003c\/p\u003e","brand":"Cheplapharm","offers":[{"title":"Default Title","offer_id":51730202853703,"sku":"023589043","price":11.01,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/cheplapharm-arzneimittel-gmbh-streptosil-neomicina-2-0-5-20-g-unguento-farmacia-dottor-tili-1213791441.jpg?v=1767138250"},{"product_id":"metronidazolo-same-1-30-g-gel","title":"Metronidazole Same 1% 30g gel","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMETRONIDAZOLE SAME is indicated for topical application in the treatment of inflammatory papules, pustules and erythema of rosacea.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of gel contains: Active ingredient: METRONIDAZOLE 1.0 g. \u003cu\u003eExcipient with known effects\u003c\/u\u003e: methyl parahydroxybenzoate (E218) (0.18 g per 100 g). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOctyldodecanol, caprylocaproyl macrogol-8 glycerides, carbomer, methyl parahydroxybenzoate (E218), sodium hydroxide, sodium edetate, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients. Contraindicated during pregnancy and breastfeeding (see p.4.6).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eApply 1-2 times a day, according to medical indications and after cleansing the affected areas, a thin layer of METRONIDAZOLE SAME. Significant therapeutic results should be observed within three weeks of starting treatment. Clinical studies have demonstrated progressive improvement for up to nine weeks of therapy. After applying METRONIDAZOLE SAME it is possible to use cosmetics.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not freeze or refrigerate.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHowever, due to the minimal absorption of Metronidazole applied locally and, consequently, the negligible plasma concentrations, the side effects reported following oral administration of the drug were not recorded following topical application. Avoid contact with eyes and mucous membranes; Metronidazole applied to the face has been reported to cause tearing. In case of contact with eyes, the gel must be carefully removed with water. The patient should be informed that if irritation occurs, he or she should use Metronidazole Same less frequently or temporarily suspend therapy and inform the doctor. Avoid exposure to ultraviolet light (sun, UV lamps, tanning equipment) during therapy with Metronidazole Same. Since the drug is a nitroimidazole derivative it must be used with caution in patients presenting with blood dyscrasias or with anamnestic data relating to them. The product must be used according to the instructions provided by the treating doctor. Do not exceed the recommended doses. The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. There are no adequate clinical data on the efficacy and safety of Metronidazole Same in children, therefore Metronidazole Same should not be used in children. Do not ingest. Keep out of reach of children. This medicine contains methyl parahydroxybenzoate, which may cause allergic reactions (possibly delayed).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn consideration of the low blood levels resulting from the topical application of Metronidazole, interactions with other drugs are unlikely. However, it must be remembered that disulfiram-like reactions have been reported in a small number of patients taking metronidazole and alcohol at the same time and in the case of treatment of patients undergoing anticoagulant therapy at the same time, it must be kept in mind that Metronidazole, following oral administration, determines an enhancement of the anticoagulant effects of coumarins and warfarin which manifests itself by inducing a prolongation of the prothrombin time. The effect of topical metronidazole on prothrombin time is not known.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFollowing the use of topical Metronidazole, the following side effects have been reported: Skin and subcutaneous tissue disorders: contact dermatitis, dry skin, erythema, itching, rash, skin discomfort (burning and stinging sensation), skin irritation, transient redness and worsening of rosacea. Eye disorders: tearing. None of these side effects occurred in more than 2% of treated patients. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported following topical application of Metronidazole.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe safety of use of metronidazole during pregnancy has not been sufficiently demonstrated. Conflicting reports are available, especially regarding the early stage of pregnancy. Some studies have given indications of an increased rate of malformations. The risk of possible sequelae, including a carcinogenic risk, has not yet been clarified. Metronidazole Same is contraindicated during the first trimester of pregnancy. During the middle trimester and during the last trimester of pregnancy, Metronidazole Same should be administered only in case of failure of other treatments. Following oral administration, Metronidazole is secreted into breast milk in concentrations similar to those found in plasma. Following topical application the drug reaches plasma levels significantly lower than those obtained after oral administration, therefore the treating doctor will have to decide whether to interrupt breastfeeding or treatment with the drug by appropriately evaluating the importance of the therapeutic treatment for the mother.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMetronidazole Same does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Savoma","offers":[{"title":"Default Title","offer_id":51730203312455,"sku":"028523013","price":15.68,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/savoma-metronidazolo-same-1-30-g-gel-farmacia-dottor-tili-1258975901.jpg?v=1789560492"},{"product_id":"rozex-0-75-50-g-crema","title":"Rozex 0.75% 50g cream","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRozex 0.75% cream is indicated in the topical treatment of rosacea in its erythematous and papulopustular manifestations.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of cream contains: \u003cu\u003eActive Ingredient:\u003c\/u\u003e Metronidazole 0.75 g Excipients with known effects: Cetylstearyl alcohol 81-106 mg\/g One gram of cream contains 22 mg of benzyl alcohol (E1519). For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEmulsified waxes (cetylstearyl alcohol and polysorbate 60), 70% non-crystallized sorbitol, glycerol, isopropyl palmitate, benzyl alcohol (E1519), lactic acid and\/or sodium hydroxide to adjust the pH, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eApply twice a day, morning and evening, a thin layer of Rozex 0.75% cream to the affected area, properly cleansed with a delicate cleanser, rubbing lightly. After applying Rozex 0.75% cream you can use non-comedogenic and non-astringent cosmetics. Treatment in elderly patients does not require dosage adjustment. During clinical use, improvements occurred within the first three weeks of treatment and continued progressively through the 12th week. The average duration of treatment usually varies from three to four months. The recommended duration of treatment should not be exceeded. However, in the event that a clear benefit has been demonstrated, the treatment can be extended according to medical opinion for a further period which varies from three to four months based on the severity of the condition. In clinical trials, topical metronidazole therapy for the treatment of rosacea was continued for up to two years. In the absence of evident clinical improvement, therapy should be discontinued. \u003ci\u003ePediatric population\u003c\/i\u003e In the absence of data on safety and efficacy, the use of Rozex 0.75% cream is not recommended in children.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAvoid contact with eyes and mucous membranes. During therapy with metronidazole, avoid exposure to UV rays (exposure to sun rays, solariums and sun lamps). Metronidazole converts into an inactive metabolite as a result of UV exposure, therefore its effectiveness decreases significantly. No side effects of phototoxicity have been reported in clinical studies in relation to metronidazole. If a reaction due to local irritation should occur, it is advisable to reduce the number of daily applications of the drug or to suspend administration according to the doctor's opinion. Metronidazole is a nitroimidazole compound and should therefore be used with caution in patients with blood dyscrasia. Avoid unnecessary and prolonged use of this medicine. Metronidazole has been shown to be carcinogenic in some animal species. There are no data demonstrating its carcinogenic effect in humans. \u003cb\u003eImportant information about some excipients.\u003c\/b\u003e \u003cb\u003eRozex 0.75% cream contains: cetylstearyl alcohol which may cause localized skin reactions (e.g. contact dermatitis). This medicinal product also contains 22 mg of benzyl alcohol (E1519) per gram, equivalent to 2.2% w\/w, which may cause allergic reactions and mild local irritation.\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eConsidering the poor systemic absorption of Rozex 0.75% cream applied topically, negative interactions with other drugs are quantitatively irrelevant. Metronidazole administered orally can lead to an enhancement of the effects of anticoagulant drugs. An increase in prothrombin time has been observed after concomitant administration of oral metronidazole and an oral coumarin-type anticoagulant (Warfarin). The effect of topical metronidazole on prothrombin time is unknown. Furthermore, in a small number of patients taking oral metronidazole and alcohol at the same time, a reaction similar to that which occurs with Disulfiram occurred.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOnly mild local reactions occurred during topical use of Rozex 0.75% cream. The following spontaneous adverse reactions have been reported and these are ranked by frequency within system organ classes, according to the following convention: very common (≥ 1\/10) common (≥ 1\/100, \u003c 1\/10) uncommon (≥ 1\/1,000, \u003c 1\/100) rare (≥ 1\/10,000, \u003c 1\/1,000) very rare (\u003c 1\/10,000) not known (frequency cannot be estimated from the available data) \u003cu\u003ePathology of the skin and subcutaneous tissue:\u003c\/u\u003e Common: dry skin, erythema, pruritus, skin discomfort (burning, skin pain, stinging), skin irritation, worsening of rosacea. Not known: contact dermatitis, skin exfoliation, facial swelling. \u003cu\u003eNervous system disorders:\u003c\/u\u003e Uncommon: hypoesthesia, paraesthesia, dysgeusia (metallic taste).\u003cu\u003eGastrointestinal disorders:\u003c\/u\u003e Uncommon: nausea. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported with the topical use of Rozex 0.75% cream in humans. Acute oral toxicity studies with topical metronidazole gel formulation at 0.75% w\/w in rats did not show toxic action at doses up to 5 g maximum administered dose of finished product per kilo body weight. This dose is equivalent to the oral intake of 12 tubes of 30 g of Rozex cream for an adult weighing 72 kg and 2 tubes of 30 g for a child weighing 12 kg.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e In animal studies, metronidazole administered orally crosses the placenta, enters the fetal circulation and was neither teratogenic nor embryotoxic at therapeutic doses; since there are no clinical data on the effects of topical preparations administered during pregnancy, during this period the drug must be used only in cases of actual need under the direct supervision of a doctor. \u003cu\u003eBreastfeeding\u003c\/u\u003e After oral administration, concentrations of metronidazole in breast milk are similar to those found in plasma. Regarding the topical administration of Rozex 0.75% cream during breastfeeding, it is advisable to evaluate the possibility of suspending breastfeeding or the use of the drug depending on actual needs, even if the serum levels of the drug are significantly reduced compared to the levels achieved following oral administration.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRozex 0.75% cream does not alter the ability to drive or use machines.\u003c\/p\u003e","brand":"Galderma","offers":[{"title":"Default Title","offer_id":51730203869511,"sku":"028809085","price":37.91,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/galderma-italia-spa-rozex-0-75-50-g-crema-farmacia-dottor-tili-1213791418.jpg?v=1767138750"},{"product_id":"fitostimoline-15-32-g-crema-garze-impregnate","title":"Fitostimoline 15% 32 g cream + impregnated gauze","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eFITOSTIMOLINES 15% Cream and FITOSTIMOLINES 15% Impregnated gauzes\u003c\/b\u003e: treatment of ulcers and bedsores\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePHYTOSTIMOLINES 15% Cream 100 g of cream contain the following active ingredient: aqueous extract of Triticum vulgare (dry residue equal to 200 mg\/100 ml) 15 g. Excipients: cetyl alcohol; stearyl alcohol. \u003cb\u003ePHYTOSTIMOLINES 15 % Impregnated gauzes\u003c\/b\u003e Each gauze is impregnated to saturation with 4 g of cream containing, in 100 g, the following active ingredient: aqueous extract of Triticum vulgare (dry residue equal to 200 mg\/100 ml) 15 g. For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePHYTOSTIMOLINES 15% Cream\u003c\/b\u003e 2–phenoxyethanol; macrogol 400; macrogol 1500; macrogol 3000; macrogol 4000; liquid paraffin; \u003cb\u003ecetyl alcohol; stearyl alcohol\u003c\/b\u003e; glycerine; purified water. \u003cb\u003ePHYTOSTIMOLINES 15 % Impregnated gauzes\u003c\/b\u003e 2–phenoxyethanol; macrogol 400; macrogol 600; macrogol 1500; macrogol 4000; glycerine; purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance to any of the excipients.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePHYTOSTIMOLINES 15% Cream\u003c\/b\u003e: The treatment involves at least two applications of cream per day. These applications, depending on the entity, extension and location of the manifestations, can be reduced to simple absorption massages, just as it may be necessary to cover the area according to the suggested application methods. • \u003ci\u003eApplication methods\u003c\/i\u003e: To open the tube for the first time, pierce the protective membrane of the tube using the perforator contained in the upper part of the closing cap. Spread as much cream as necessary on the area and cover with sterile gauze, possibly soaked in the same cream in order to maintain the softness and plasticity of the application. In subsequent dressings, unless there are specific contraindications, the area can be washed beforehand with simple sterile water, as the cream is completely water-dispersible and leaves no residue. \u003cb\u003ePHYTOSTIMOLINES 15 % Impregnated gauzes\u003c\/b\u003e: The treatment ranges from one to two applications per day, taking care that the dressing always remains moist, soft and plastic. • \u003ci\u003eApplication methods\u003c\/i\u003e: Take the gauze with sterile forceps and apply it directly to the previously cleansed and disinfected area. Cover with sterile gauze and then with cotton wool (in the case of very secreting sores). In subsequent dressings, unless there are specific contraindications, the area can be washed beforehand with sterile water only, as the cream is completely water-dispersible and leaves no residue.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePHYTOSTIMOLINES 15% Cream: \u003c\/b\u003estore the product at a temperature not exceeding 30°C. \u003cb\u003ePHYTOSTIMOLINES 15 % Impregnated gauzes\u003c\/b\u003e: store the product at a temperature not exceeding 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use, especially if prolonged, of all products for topical use can give rise to sensitization phenomena. If this occurs, treatment should be suspended and appropriate therapy instituted, if necessary. The same applies in the case of the development of insensitive germs. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e \u003cb\u003ePhytostimolines 15% Cream \u003c\/b\u003econtains cetyl and stearyl alcohol: they may cause localized skin reactions (e.g. contact dermatitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known interactions or incompatibilities.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo side clinical manifestations or unwanted secondary effects have been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eFITOSTIMOLINES 15% Cream and FITOSTIMOLINES 15% Impregnated gauzes\u003c\/b\u003e they can be used without problems during pregnancy and breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eFITOSTIMOLINES 15% Cream and FITOSTIMOLINES 15% Impregnated gauzes \u003c\/b\u003ethey do not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Damor","offers":[{"title":"Default Title","offer_id":51730204098887,"sku":"009115027","price":17.1,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/farmaceutici-damor-spa-fitostimoline-15-32-g-crema-garze-impregnate-farmacia-dottor-tili-1213791412.jpg?v=1767138869"},{"product_id":"carexidil-5-60-ml-spray-cutaneo-soluzione","title":"Carexidil 5% 60 ml cutaneous spray solution","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCarexidil is indicated in the symptomatic treatment of androgenic alopecia in men and women. The efficacy of Carexidil has not been determined in the following forms: localized or generalized congenital alopecia; cicatricial alopecia of various nature (post-traumatic, of psychic or infectious origin); acute alopecia spread by toxic substances, by medicines in which hair regrowth is conditioned by the suppression of the specific cause; Celtic area.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 ml of carexidil 5% skin spray, solution contains 5 g of minoxidil. Excipients with known effects: ethyl alcohol For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eEthyl alcohol (96%),\u003c\/b\u003e glycerol, 2-butenedioic acid polymer with methoxyethene, monobutyl ester and purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to minoxidil or to any of the excipients listed in paragraph 6.1 Carexidil must not be used in the presence of coronary heart disease, arrhythmias, congestive heart failure or valve disease. Do not use during pregnancy and breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e Apply a dose of 1 ml of Carexidil twice a day, preferably in the morning and evening, to the affected areas of the scalp. The dose is independent of the size of the area to be treated. The total daily dose should not exceed 2 ml. Before evidence of hair growth can be expected, it may be necessary to wait 3-4 months of twice daily applications. The onset of these signs and their intensity vary from patient to patient. In all cases, the doctor must evaluate the opportunity to suspend treatment if no therapeutic result is observed within 4 months. If regrowth occurs, you must continue applying Carexidil twice daily for hair growth to continue. Relapse to the pre-treatment state following discontinuation of therapy occurs within 3-4 months. \u003ci\u003eSpecial populations\u003c\/i\u003e The use of Carexidil is not recommended in patients over 55 years of age due to a lack of data on safety and efficacy. \u003ci\u003ePediatric population\u003c\/i\u003e The use of Carexidil is not recommended in children under 18 years of age, due to a lack of data on safety and efficacy. \u003cu\u003eMethod of administration\u003c\/u\u003e Use Carexidil only as directed. Apply Carexidil only to completely dry hair and scalp. Hair should not be washed after applying Carexidil. Do not apply Carexidil to other areas of the body. After applying Carexidil, wash your hands carefully. During treatment with Carexidil, other cosmetic hair products can be used, following the instructions below: - use a delicate shampoo. - it is necessary to allow Carexidil to penetrate the scalp before using hair styling products. Do not mix with other preparations to be applied to the scalp. - there is no information available on whether treatments \u003cu\u003ewith hair dye or permanent\u003c\/u\u003e alter the effect of Carexidil. However, to avoid possible scalp irritation, the patient should ensure that Carexidil has been completely washed off the hair and scalp before using these chemicals. \u003cu\u003eInstructions for use\u003c\/u\u003e 10 pulses are equivalent to 1 ml of solution delivered. Unscrew the white polypropylene cap. Insert the spray applicator onto the bottle and screw firmly. Apply the extender to the stem, press to secure it firmly. Direct the extender towards the area to be treated, spray once and distribute Carexidil with your fingertips on the area to be treated. Repeat the operation a total of 10 times to achieve the application of a dose of 1 ml of solution. Avoid inhaling vapours.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo special precautions for storage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatients who are scheduled to undergo therapy with Carexidil should have a medical history and undergo physical examinations. The doctor should determine that the patient has a normal, healthy scalp, such as not red, inflamed, infected, irritated, or painful. Minoxidil is not indicated when there is no family history of hair loss, the hair loss is sudden and\/or patchy, caused by childbirth, or when its cause is unknown. With the use of minoxidil, some patients have experienced changes in the color and\/or texture of their hair. Increased hair loss may occur due to minoxidil's action of changing hair from the resting telogen phase to the anagen growth phase (old hair falls out as new hair grows in its place). Generally this temporary increase in hair loss occurs between two and six weeks after starting treatment and reduces within a couple of weeks (first sign of minoxidil's effectiveness). If hair loss persists, users should stop using Carexidil and consult their doctor. The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. In this case, stop treatment and consult your doctor to institute suitable therapy. Although extensive clinical studies with minoxidil have not demonstrated that there is sufficient absorption of this active ingredient to cause systemic effects, some absorption of minoxidil occurs through the scalp and there is a potential risk of systemic effects such as salt and fluid retention, generalized and local edema, pericardial effusion, pericarditis, cardiac tamponade, tachycardia, angina or increased orthostatic hypotension induced by antihypertensive drugs such as guanethidine and derivatives. In the presence of cardiovascular disorders, including hypertension, careful medical evaluation is necessary. The patient should stop using Carexidil and consult a doctor if hypotension is detected or if the patient experiences chest pain, rapid heartbeat, weakness, dizziness, sudden and unexplained weight gain, swollen hands or feet, persistent redness, dermatological reactions or scalp irritation, or if other unexpected new symptoms occur (see section 4.8). Patients with a history of underlying cardiac disorders should be warned that Carexidil may worsen these disorders. Patients should be monitored periodically for any suspicion of systemic effects caused by minoxidil. Accidental ingestion may cause serious cardiac adverse events. Patients should avoid inhaling the product when using the spray applicator. In the event of systemic side effects or dermatological reactions, discontinue administration of the drug. Unwanted hair growth may be caused by transfer of the product to areas other than the scalp. \u003cu\u003eImportant information about some excipients\u003c\/u\u003e Carexidil 5% skin spray, solution contains: § ethyl alcohol: may cause burning and irritation of the eyes. In case of accidental contact with sensitive surfaces (eyes, abraded skin and mucous membranes), the area should be wetted with large quantities of fresh tap water\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCarexidil should not be used concomitantly with other medicines applied topically to the scalp (corticosteroids, tretinoin and antralin). No other interactions associated with the use of minoxidil are currently known. Although not demonstrated clinically, there is a potential for increased orthostatic hypotension in patients receiving concomitant therapy with peripheral vasodilators.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe frequency of adverse reactions to minoxidil for topical use is defined using the following convention: very common (≥ 1\/10); common (≥ 1\/100, \u003c 1\/10); uncommon (≥ 1\/1,000, \u003c 1\/100); rare (≥ 1\/10,000, \u003c 1\/1,000); very rare (\u003c 1\/10,000); not known (frequency cannot be estimated from the available data). \u003cb\u003e \u003ci\u003eAdverse reactions reported during clinical trials\u003c\/i\u003e \u003c\/b\u003eThe safety of minoxidil for cutaneous use is based on data from 7 randomized placebo-controlled clinical trials in adults evaluating minoxidil 2% and 5% solution (Table 1), and two randomized placebo-controlled clinical trials in adults evaluating minoxidil cutaneous foam 5% (Table 2).\u003cb\u003eTable 1\u003c\/b\u003e: Adverse reactions recorded with a frequency ≥1% in adult subjects treated with Minoxidil with 2% or 5% solution topically, in randomized placebo-controlled clinical trials are reported.\u003c\/p\u003e\n\u003cp\u003eAdverse reactions - Frequency: Frequency.\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003ePeripheral edema - Frequency: Common.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders.\u003c\/p\u003e\n\u003cp\u003eHeadache - Frequency: Very common.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eDyspnea - Frequency: Common.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eDermatitis, Dermatitis acneiform, Hypertrichosis, Pruritus, Rash - Frequency: Common.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eTable 2\u003c\/b\u003e: adverse reactions recorded with a frequency ≥1% in adult subjects treated with Minoxidil with 5% foam topically, in randomized placebo-controlled clinical trials are reported.\u003c\/p\u003e\n\u003cp\u003eAdverse reactions - Frequency: Frequency.\u003c\/p\u003e\n\u003cp\u003eDiagnostic tests.\u003c\/p\u003e\n\u003cp\u003eWeight gain - Frequency: Common.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders.\u003c\/p\u003e\n\u003cp\u003eHeadache - Frequency: Common.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eItching, Rash - Frequency: Common.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003ci\u003eAdverse reactions reported during post-marketing experience\u003c\/i\u003e \u003c\/b\u003e Nella \u003cb\u003eTable 3\u003c\/b\u003e, the adverse reactions collected in post-marketing experience are reported, frequency based on the incidence of spontaneous reports\u003c\/p\u003e\n\u003cp\u003eNervous system disorders.\u003c\/p\u003e\n\u003cp\u003eFrequency: Uncommon. Adverse reactions: Dizziness, Vertigo, Tingling, Neuritis, Taste changes, Burning sensation.\u003c\/p\u003e\n\u003cp\u003eEye pathologies.\u003c\/p\u003e\n\u003cp\u003eFrequency: Uncommon. Adverse reactions: Visual disturbances.\u003c\/p\u003e\n\u003cp\u003eFrequency: Rare. Adverse reactions: Eye irritation.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders.\u003c\/p\u003e\n\u003cp\u003eFrequency: Uncommon. Adverse reactions: Ear infection, Otitis externa.\u003c\/p\u003e\n\u003cp\u003eVascular pathologies.\u003c\/p\u003e\n\u003cp\u003eFrequency: Municipalities. Adverse reactions: Hypertension.\u003c\/p\u003e\n\u003cp\u003eFrequency: Uncommon. Adverse reactions: Hypotension.\u003c\/p\u003e\n\u003cp\u003eCardiac diseases.\u003c\/p\u003e\n\u003cp\u003eFrequency: Rare. Adverse reactions: Palpitations, Tachycardia.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eFrequency: Very rare. Adverse reactions: Nausea, Vomiting.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders.\u003c\/p\u003e\n\u003cp\u003eFrequency: Rare. Adverse reactions: Hepatitis.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders.\u003c\/p\u003e\n\u003cp\u003eFrequency: Rare. Adverse reactions: Kidney stones.\u003c\/p\u003e\n\u003cp\u003eReproductive system and breast disorders.\u003c\/p\u003e\n\u003cp\u003eFrequency: Rare. Adverse reactions: Sexual dysfunction.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eFrequency: Uncommon. Adverse reactions: Irritation, Pain, Erythema, Edema Skin scaling, Eczema, Allergic reaction, Sensitization, Urticaria, Generalized erythema and Edema of the face. Dermatitis (including contact, application site, allergic, atopic and seborrheic dermatitis). Dry skin (including application site dryness), Blisters, Acne.\u003c\/p\u003e\n\u003cp\u003eFrequency: Rare. Adverse reactions: Bleeding and ulceration, Vesiculation, Exacerbation of hair loss, Alopecia.\u003c\/p\u003e\n\u003cp\u003eFrequency: Very rare. Adverse reactions: Temporary hair loss, Changes in hair color, Abnormal hair structure.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eFrequency: Very rare. Adverse reactions: Angioedema, Hypersensitivity, Contact dermatitis.\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eFrequency: Uncommon. Adverse reactions: Weakness.\u003c\/p\u003e\n\u003cp\u003eFrequency: Very rare. Adverse reactions: Chest pain.\u003c\/p\u003e\n\u003cp\u003eThe nature and severity of the reactions detected are similar in the treatment with 2% and 5% minoxidil, but their incidence is higher in the latter. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf higher than recommended doses of Carexidil are applied or to areas of the body other than the scalp, increased systemic absorption of minoxidil may potentially occur. Accidental ingestion of minoxidil can lead to serious side effects. Following accidental ingestion, minoxidil is totally absorbed through the gastrointestinal tract and can cause systemic effects related to its vasodilatory action. The signs and symptoms of minoxidil overdose are mainly cardiovascular associated with sodium and fluid retention and tachycardia, hypotension, weakness and dizziness may also occur. \u003cb\u003eTreatment\u003c\/b\u003e Treatment of minoxidil overdose should be symptomatic and supportive. Fluid retention can be treated with appropriate diuretic therapy. Tachycardia can be controlled by administering a beta-blocking agent. Hypotension can be treated with intravenous administration of normal saline. Drugs with sympathomimetic action, such as norepinephrine and adrenaline, must be avoided due to their excessive cardiac stimulating activity.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCarexidil should not be used during pregnancy and breastfeeding and in women of childbearing age who do not use contraceptives. \u003cu\u003ePregnancy \u003c\/u\u003e There are no adequate and well-controlled studies in pregnant women. Animal studies have shown a risk to the fetus at exposure levels much higher than those intended for human exposure (see section 5.3). The potential risk in humans is unknown. \u003cu\u003eBreastfeeding\u003c\/u\u003e Systemically absorbed minoxidil is excreted in breast milk. The effect of minoxidil on newborns\/children is unknown. \u003cu\u003eFertility\u003c\/u\u003e There are no adequate and well-controlled studies regarding female fertility. Animal studies have shown fertility toxicity, a reduction in conception and implantation rates, as well as a reduction in the number of live offspring at exposure levels much higher than those intended for human exposure (see section 5.3). The potential risk in humans is unknown.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBased on the pharmacodynamics and overall safety profile of minoxidil, Carexidil is not expected to interfere with the ability to drive or use machinery.\u003c\/p\u003e","brand":"Difa Cooper","offers":[{"title":"Default Title","offer_id":51730204328263,"sku":"037291010","price":37.91,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/difa-cooper-spa-carexidil-5-60-ml-spray-cutaneo-soluzione-farmacia-dottor-tili-1213791370.jpg?v=1767138989"},{"product_id":"verunec-15-g-15-g-100-g-10-g-collodio","title":"Verunec 15 g + 15 g\/100 g 10 g collodion","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment of vulgar, plantar and mosaic warts; calluses and calluses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of collodion contain: Active ingredients: SALICYLIC ACID 15 g, LACTIC ACID 15 g.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUrea, glycerin, elastic collodion USP (composed of camphor, castor oil, pyroxylin, ethyl ether, ethyl alcohol).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients. VERUNEC should not be used by diabetics or patients with impaired blood circulation. VERUNEC, like all products with a high salicylic acid content, should not be applied to the face and anogenital area.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eApply a small quantity of product to the affected area twice a day (morning and evening), using the appropriate spatula. Allow to evaporate for a few minutes. VERUNEC leaves a protective film that does not require particular attention and is easily removable during subsequent applications. It is recommended, before using the product, to wet the application area for about 5 minutes in hot water and, from time to time (2-3 times a week), to rub it with a stone or abrasive file. The treatment must be continued until the callus is completely removed. Do not exceed the recommended doses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product is flammable, keep the bottle tightly closed and away from flames or heat sources.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product must not be applied on: seborrheic warts, facial warts, warts, skin nevi. Avoid contact with eyes and mucous membranes. If the product is spilled into the eyes or on the mucous membranes, wash with water, remove the precipitated collodion and wash again with water for 15 minutes. Avoid application on normal skin surrounding the callus. The product is for external use only. The use, especially prolonged, of products for topical use can give rise to sensitization phenomena. In this case, stop treatment and consult your doctor to institute suitable therapy. Do not ingest. In case of accidental ingestion of the product, consult a doctor immediately. The product must not be used to prevent the formation of warts. Keep out of reach of children. Do not use for prolonged treatments; after a short period of treatment without appreciable results, consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAvoid the simultaneous use of other keratolytics so as not to increase the caustic action of the active substances.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocalized irritation may occur if the product is applied to the skin surrounding the hyperkeratotic formation. Normally irritation should be controlled by temporary suspension and application of the product only to the affected area when treatment is resumed.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported. However, if an excessive dose of product is applied, wash immediately and carefully with water and consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe safety of use during pregnancy has not been established, therefore the product should only be used if clearly necessary and under the supervision of a doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known effects on the ability to drive and use machines.\u003c\/p\u003e","brand":"Savoma","offers":[{"title":"Default Title","offer_id":51730204754247,"sku":"034603011","price":11.5,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/savoma-verunec-15-g-15-g-100-g-10-g-collodio-farmacia-dottor-tili-1254215768.jpg?v=1786736413"},{"product_id":"fitostimoline-15-10-garze-impregnate-crema","title":"Fitostimoline 15% 10 gauzes impregnated with cream","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eFITOSTIMOLINES 15% Cream and FITOSTIMOLINES 15% Impregnated gauzes\u003c\/b\u003e: treatment of ulcers and bedsores\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePHYTOSTIMOLINES 15% Cream 100 g of cream contain the following active ingredient: aqueous extract of Triticum vulgare (dry residue equal to 200 mg\/100 ml) 15 g. Excipients: cetyl alcohol; stearyl alcohol. \u003cb\u003ePHYTOSTIMOLINES 15 % Impregnated gauzes\u003c\/b\u003e Each gauze is impregnated to saturation with 4 g of cream containing, in 100 g, the following active ingredient: aqueous extract of Triticum vulgare (dry residue equal to 200 mg\/100 ml) 15 g. For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePHYTOSTIMOLINES 15% Cream\u003c\/b\u003e 2–phenoxyethanol; macrogol 400; macrogol 1500; macrogol 3000; macrogol 4000; liquid paraffin; \u003cb\u003ecetyl alcohol; stearyl alcohol\u003c\/b\u003e; glycerine; purified water. \u003cb\u003ePHYTOSTIMOLINES 15 % Impregnated gauzes\u003c\/b\u003e 2–phenoxyethanol; macrogol 400; macrogol 600; macrogol 1500; macrogol 4000; glycerine; purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance to any of the excipients.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePHYTOSTIMOLINES 15% Cream\u003c\/b\u003e: The treatment involves at least two applications of cream per day. These applications, depending on the entity, extension and location of the manifestations, can be reduced to simple absorption massages, just as it may be necessary to cover the area according to the suggested application methods. • \u003ci\u003eApplication methods\u003c\/i\u003e: To open the tube for the first time, pierce the protective membrane of the tube using the perforator contained in the upper part of the closing cap. Spread as much cream as necessary on the area and cover with sterile gauze, possibly soaked in the same cream in order to maintain the softness and plasticity of the application. In subsequent dressings, unless there are specific contraindications, the area can be washed beforehand with simple sterile water, as the cream is completely water-dispersible and leaves no residue. \u003cb\u003ePHYTOSTIMOLINES 15 % Impregnated gauzes\u003c\/b\u003e: The treatment ranges from one to two applications per day, taking care that the dressing always remains moist, soft and plastic. • \u003ci\u003eApplication methods\u003c\/i\u003e: Take the gauze with sterile forceps and apply it directly to the previously cleansed and disinfected area. Cover with sterile gauze and then with cotton wool (in the case of very secreting sores). In subsequent dressings, unless there are specific contraindications, the area can be washed beforehand with sterile water only, as the cream is completely water-dispersible and leaves no residue.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePHYTOSTIMOLINES 15% Cream: \u003c\/b\u003estore the product at a temperature not exceeding 30°C. \u003cb\u003ePHYTOSTIMOLINES 15 % Impregnated gauzes\u003c\/b\u003e: store the product at a temperature not exceeding 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use, especially if prolonged, of all products for topical use can give rise to sensitization phenomena. If this occurs, treatment should be suspended and appropriate therapy instituted, if necessary. The same applies in the case of the development of insensitive germs. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e \u003cb\u003ePhytostimolines 15% Cream \u003c\/b\u003econtains cetyl and stearyl alcohol: they may cause localized skin reactions (e.g. contact dermatitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known interactions or incompatibilities.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo side clinical manifestations or unwanted secondary effects have been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eFITOSTIMOLINES 15% Cream and FITOSTIMOLINES 15% Impregnated gauzes\u003c\/b\u003e they can be used without problems during pregnancy and breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eFITOSTIMOLINES 15% Cream and FITOSTIMOLINES 15% Impregnated gauzes \u003c\/b\u003ethey do not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Damor","offers":[{"title":"Default Title","offer_id":51730204787015,"sku":"009115039","price":19.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/farmaceutici-damor-spa-fitostimoline-15-10-garze-impregnate-crema-farmacia-dottor-tili-1213791393.jpg?v=1767139210"},{"product_id":"benzac-gel-10-40-g-gel","title":"Benzac Gel 10% 40g gel","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSkin disinfection. It also has antiseptic activity against P. acnes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of gel contains:\u003c\/p\u003e\n\u003cp\u003eActive ingredient: Benzoyl Peroxide - BENZAC 10% gel: 10 g. BENZAC 5% gel: 5 g.\u003c\/p\u003e\n\u003cp\u003eExcipient with known effects: Propylene glycol (E1520) For the complete list of excipients, see paragraph 6.1 Rinse-off formulation 100 g of gel contain:\u003c\/p\u003e\n\u003cp\u003eActive ingredient: BENZAC 5% gel.\u003c\/p\u003e\n\u003cp\u003eBenzoyl Peroxide: 5 g.\u003c\/p\u003e\n\u003cp\u003eFor the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENZAC 5% gel and BENZAC 10% gel\u003c\/b\u003e Carbomer 940, Methacrylic copolymer, Glycerin, Disodium Edetate, Dioctyl sodium sulfosuccinate, Colloidal silica, Propylene glycol (E1520), Poloxamer 182, Demineralised water. \u003cb\u003eBENZAC 5% gel - rinse-off formulation\u003c\/b\u003e Acryl Copolymer, Carbomer 940, Sodium C14-C16 Olefin Sulphonate, Glycerol, Sodium Hydroxide, Demineralised Water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENZAC 5% gel\u003c\/b\u003e e \u003cb\u003eBENZAC 10% gel\u003c\/b\u003e: Apply Benzac locally on the skin, favoring its penetration with a light massage. Applications must be made once or twice a day, as needed, by spreading a small amount of Benzac with the fingertips on the affected parts, previously thoroughly cleaned with a mild detergent and dried carefully, massaging lightly until absorbed. People with sensitive skin should apply the gel once a day or once every two days before going to bed. \u003cb\u003eBENZAC 5% gel (rinse-off formulation)\u003c\/b\u003e: Apply the gel once or twice a day to the affected area. Moisten the application area. Place the required amount of BENZAC 5% gel on your fingertips and spread it on the various parts of the skin with a circular motion, as if washing. Skin contact time should be as short as possible (1 to 5 minutes) to minimize the risk of undesirable effects (see section 4.8). Rinse thoroughly with water and dry.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store Benzac above 25°C\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenzac is for external use only. The use, especially if prolonged, of products for skin use can give rise to sensitization phenomena; in this case, stop treatment and consult your doctor to institute suitable therapy. Probably, at the first application you may feel a slight burning sensation and, within a few days, slight redness and peeling of the skin may occur. During the first weeks of treatment, a sudden increase in desquamation occurs in most patients. This is not dangerous and normally subsides within a day or two if treatment is temporarily stopped. Patients should be directed to use the drug less frequently, to temporarily discontinue or discontinue use, if severe irritation occurs. Benzoyl peroxide may cause swelling and blistering of the skin; if any of these symptoms occur, the medicine should be stopped. Avoid contact with eyes, mouth, corners of the nose and other mucous membranes. If the medicine gets into the eye, wash with plenty of water. Caution should be used when applying the medicine to the neck and other sensitive areas. The oxidizing action of the gel can discolor dyed hair and colored clothing. Do not apply to abraded or irritated skin. Avoid exposure to the sun and ultraviolet rays while applying benzoyl peroxide. \u003cu\u003ePediatric population\u003c\/u\u003e: No efficacy and safety data are available in children under 12 years of age. \u003cb\u003eBenzac 5% gel and Benzac 10% gel contain propylene glycol\u003c\/b\u003e Benzac 5% gel and Benzac 10% gel contain 4% propylene glycol, corresponding to 40 mg for each gram of gel.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAvoid the simultaneous use of strong detergents, alcoholic products, anti-acne skin preparations and medicines used in the treatment of acne containing substances that can increase the effect \u003ci\u003epeeling,\u003c\/i\u003e irritants or that cause skin dryness, such as those based on tretinoin, resorcinol, salicylic acid and sulphides, medicated cosmetics.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe adverse reactions resulting from clinical studies are all related to skin disorders. They are reversible if treatment is reduced in frequency or stopped. The frequency of adverse reactions is divided into the following categories: Very common (≥1\/10); Common (≥1\/100, \u003c1\/10); Uncommon (≥1\/1,000, \u003c1\/100); Rare (≥1\/10,000, \u003c1\/1,000); Very rare (\u003c1\/10,000); Not known (frequency cannot be estimated from the available data). Adverse reactions are shown in the table below:\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eVery common: erythema, skin exfoliation (desquamation), burning sensation of the skin, dry skin.\u003c\/p\u003e\n\u003cp\u003eCommon: Skin irritation (irritant contact dermatitis), pruritus, skin pain (pain, stinging).\u003c\/p\u003e\n\u003cp\u003eUncommon: allergic contact dermatitis.\u003c\/p\u003e\n\u003cp\u003eCases of facial swelling and allergic reactions, including application site hypersensitivity and anaphylaxis, have been reported (frequency not known) from post-marketing pharmacovigilance data. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenzac is for cutaneous use only. Excessive application of the product does not lead to faster or better results but may cause irritation. If severe irritation develops, treatment should be discontinued and appropriate symptomatic therapy instituted.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFertility, pregnancy: There are no safety concerns regarding the effects of benzoyl peroxide, applied to the skin, on reproductive function, fertility, teratogenicity, or peri- and post-natal development, in animals. Generalized clinical use for the skin treatment of acne vulgaris, for several decades, at concentrations of up to 10% w\/w of benzoyl peroxide has never been associated with such effects. In any case, the drug should be administered in cases of real need under the direct supervision of a doctor. Breastfeeding: It is not known whether benzoyl peroxide is excreted in animal or human milk. Because many drugs are excreted in breast milk, caution should be exercised when benzoyl peroxide gel is used by women who are breastfeeding. The preparation must not be applied to the breast to avoid accidental transfer to the infant.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenzac does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Galderma","offers":[{"title":"Default Title","offer_id":51730204983623,"sku":"032143012","price":23.28,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/galderma-italia-spa-benzac-gel-10-40-g-gel-farmacia-dottor-tili-1213791388.jpg?v=1767139359"},{"product_id":"trans-ver-sal-13-5-mg-12-mm-20-cerotti-transdermici-garzette-e-limetta","title":"Trans - Ver - Sal 13.5 mg\/12 mm 20 transdermal patches + egrets and lime","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor the treatment of common warts, calluses and calluses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003econtains.\u003c\/p\u003e\n\u003cp\u003eActive ingredient.\u003c\/p\u003e\n\u003cp\u003esalicylic acid mg - 6 mm: 3.75. 12mm: 13.5. 20mm: 36.3.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eKaraya gum; propylene glycol; polyethylene glycol 300 quaternium 15\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients. The product should not be used in case of diabetes or circulatory failure. Like all products with a high salicylic acid content, it should not be applied to the face, anogenital area and mucous membranes. The transdermal patch should not be applied to moles, seborrheic warts and warts.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eApply a transdermal patch to the affected area in the evening and remove it the following morning. Repeat the application every 24 hours until the wart is eliminated. Do not exceed the recommended doses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNone.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use, especially prolonged, of products for topical use can give rise to sensitization phenomena, in which case interrupt the treatment and institute a suitable therapy. Do not use for prolonged treatments, after a short period of treatment without appreciable results, consult your doctor. Avoid application on healthy skin surrounding the affected area. Keep out of reach of children. Avoid contact with eyes and mucous membranes. Do not use the product on irritated, infected or red skin. Do not ingest. In case of accidental ingestion, consult your doctor immediately. The product must not be used to prevent the formation of warts.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAvoid the simultaneous use of other keratolytics so as not to increase the caustic action of the active substance.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn some cases, intolerance (burning or irritation) may occur, however without consequences and which does not require modification of the treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBy following the instructions for use above, there is no possibility of overdose.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no limitations on use.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNobody.\u003c\/p\u003e","brand":"Difa Cooper","offers":[{"title":"Default Title","offer_id":51730205049159,"sku":"034674022","price":21.38,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/difa-cooper-spa-trans-ver-sal-13-5-mg-12-mm-20-cerotti-transdermici-garzette-e-limetta-farmacia-dottor-tili-1213791386.jpg?v=1767139426"},{"product_id":"trans-ver-sal-3-75-mg-6-mm-20-cerotti-transdermici-garzette-e-limetta","title":"Trans - Ver - Sal 3.75 mg\/6 mm 20 transdermal patches + egrets and lime","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor the treatment of common warts, calluses and calluses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003econtains.\u003c\/p\u003e\n\u003cp\u003eActive ingredient.\u003c\/p\u003e\n\u003cp\u003esalicylic acid mg - 6 mm: 3.75. 12mm: 13.5. 20mm: 36.3.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eKaraya gum; propylene glycol; polyethylene glycol 300 quaternium 15\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients. The product should not be used in case of diabetes or circulatory failure. Like all products with a high salicylic acid content, it should not be applied to the face, anogenital area and mucous membranes. The transdermal patch should not be applied to nevi, seborrheic warts and warts.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eApply a transdermal patch to the affected area in the evening and remove it the following morning. Repeat the application every 24 hours until the wart is eliminated. Do not exceed the recommended doses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNone.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use, especially prolonged, of products for topical use can give rise to sensitization phenomena, in which case interrupt the treatment and institute a suitable therapy. Do not use for prolonged treatments, after a short period of treatment without appreciable results, consult your doctor. Avoid application on healthy skin surrounding the affected area. Keep out of reach of children. Avoid contact with eyes and mucous membranes. Do not use the product on irritated, infected or red skin. Do not ingest. In case of accidental ingestion, consult a doctor immediately. The product must not be used to prevent the formation of warts.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAvoid the simultaneous use of other keratolytics so as not to increase the caustic action of the active substance.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn some cases, intolerance (burning or irritation) may occur, however without consequences and which does not require modification of the treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBy following the instructions for use above, there is no possibility of overdose.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no limitations on use.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNobody.\u003c\/p\u003e","brand":"Difa Cooper","offers":[{"title":"Default Title","offer_id":51730205114695,"sku":"034674010","price":21.38,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/difa-cooper-spa-trans-ver-sal-3-75-mg-6-mm-20-cerotti-transdermici-garzette-e-limetta-farmacia-dottor-tili-1213791384.jpg?v=1767139390"},{"product_id":"benzac-gel-5-40-g-gel","title":"Benzac Gel 5% 40g gel","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSkin disinfection. It also has antiseptic activity against P. acnes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of gel contains:\u003c\/p\u003e\n\u003cp\u003eActive ingredient: Benzoyl Peroxide - BENZAC 10% gel: 10 g. BENZAC 5% gel: 5 g.\u003c\/p\u003e\n\u003cp\u003eExcipient with known effects: Propylene glycol (E1520) For the complete list of excipients, see paragraph 6.1 Rinse-off formulation 100 g of gel contain:\u003c\/p\u003e\n\u003cp\u003eActive ingredient: BENZAC 5% gel.\u003c\/p\u003e\n\u003cp\u003eBenzoyl Peroxide: 5 g.\u003c\/p\u003e\n\u003cp\u003eFor the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENZAC 5% gel and BENZAC 10% gel\u003c\/b\u003e Carbomer 940, Methacrylic copolymer, Glycerin, Disodium Edetate, Dioctyl sodium sulfosuccinate, Colloidal silica, Propylene glycol (E1520), Poloxamer 182, Demineralised water. \u003cb\u003eBENZAC 5% gel - rinse-off formulation\u003c\/b\u003e Acryl Copolymer, Carbomer 940, Sodium C14-C16 Olefin Sulphonate, Glycerol, Sodium Hydroxide, Demineralised Water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENZAC 5% gel\u003c\/b\u003e e \u003cb\u003eBENZAC 10% gel\u003c\/b\u003e: Apply Benzac locally on the skin, favoring its penetration with a light massage. Applications must be made once or twice a day, as needed, by spreading a small amount of Benzac with the fingertips on the affected parts, previously thoroughly cleaned with a mild detergent and dried carefully, massaging lightly until absorbed. People with sensitive skin should apply the gel once a day or once every two days before going to bed. \u003cb\u003eBENZAC 5% gel (rinse-off formulation)\u003c\/b\u003e: Apply the gel once or twice a day to the affected area. Moisten the application area. Place the required amount of BENZAC 5% gel on your fingertips and spread it on the various parts of the skin with a circular motion, as if washing. Skin contact time should be as short as possible (1 to 5 minutes) to minimize the risk of undesirable effects (see section 4.8). Rinse thoroughly with water and dry.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store Benzac above 25°C\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenzac is for external use only. The use, especially if prolonged, of products for skin use can give rise to sensitization phenomena; in this case, stop treatment and consult your doctor to institute suitable therapy. Probably, at the first application you may feel a slight burning sensation and, within a few days, slight redness and peeling of the skin may occur. During the first weeks of treatment, a sudden increase in desquamation occurs in most patients. This is not dangerous and normally subsides within a day or two if treatment is temporarily stopped. Patients should be directed to use the drug less frequently, to temporarily discontinue or discontinue use, if severe irritation occurs. Benzoyl peroxide may cause swelling and blistering of the skin; if any of these symptoms occur, the medicine should be stopped. Avoid contact with eyes, mouth, corners of the nose and other mucous membranes. If the medicine gets into the eye, wash with plenty of water. Caution should be used when applying the medicine to the neck and other sensitive areas. The oxidizing action of the gel can discolor dyed hair and colored clothing. Do not apply to abraded or irritated skin. Avoid exposure to the sun and ultraviolet rays while applying benzoyl peroxide. \u003cu\u003ePediatric population\u003c\/u\u003e: No efficacy and safety data are available in children under 12 years of age. \u003cb\u003eBenzac 5% gel and Benzac 10% gel contain propylene glycol\u003c\/b\u003e Benzac 5% gel and Benzac 10% gel contain 4% propylene glycol, corresponding to 40 mg for each gram of gel.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAvoid the simultaneous use of strong detergents, alcoholic products, anti-acne skin preparations and medicines used in the treatment of acne containing substances that can increase the effect \u003ci\u003epeeling,\u003c\/i\u003e irritants or that cause skin dryness, such as those based on tretinoin, resorcinol, salicylic acid and sulphides, medicated cosmetics.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe adverse reactions resulting from clinical studies are all related to skin disorders. They are reversible if treatment is reduced in frequency or stopped. The frequency of adverse reactions is divided into the following categories: Very common (≥1\/10); Common (≥1\/100, \u003c1\/10); Uncommon (≥1\/1,000, \u003c1\/100); Rare (≥1\/10,000, \u003c1\/1,000); Very rare (\u003c1\/10,000); Not known (frequency cannot be estimated from the available data). Adverse reactions are shown in the table below:\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eVery common: erythema, skin exfoliation (desquamation), skin burning sensation, skin dryness.\u003c\/p\u003e\n\u003cp\u003eCommon: Skin irritation (irritant contact dermatitis), pruritus, skin pain (pain, stinging).\u003c\/p\u003e\n\u003cp\u003eUncommon: allergic contact dermatitis.\u003c\/p\u003e\n\u003cp\u003eCases of facial swelling and allergic reactions, including application site hypersensitivity and anaphylaxis, have been reported (frequency not known) from post-marketing pharmacovigilance data. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenzac is for cutaneous use only. Excessive application of the product does not lead to faster or better results but may cause irritation. If severe irritation develops, treatment should be discontinued and appropriate symptomatic therapy instituted.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFertility, pregnancy: There are no safety concerns regarding the effects of benzoyl peroxide, applied to the skin, on reproductive function, fertility, teratogenicity, or peri- and post-natal development, in animals. Generalized clinical use for the skin treatment of acne vulgaris, for several decades, at concentrations of up to 10% w\/w of benzoyl peroxide has never been associated with such effects. In any case, the drug should be administered in cases of real need under the direct supervision of a doctor. Breastfeeding: It is not known whether benzoyl peroxide is excreted in animal or human milk. Because many drugs are excreted in breast milk, caution should be exercised when benzoyl peroxide gel is used by women who are breastfeeding. The preparation must not be applied to the breast to avoid accidental transfer to the infant.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenzac does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Galderma","offers":[{"title":"Default Title","offer_id":51730205344071,"sku":"032143024","price":22.33,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/galderma-italia-spa-benzac-gel-5-40-g-gel-farmacia-dottor-tili-1213791382.jpg?v=1767139472"},{"product_id":"connettivina-plus-0-2-1-25-g-crema","title":"Connettivina Plus 0.2% + 1% 25 g cream","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of mild wounds. Local treatment of 1st and 2nd degree burns\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eCONNECTIVITY\u003c\/u\u003e \u003cu\u003ePLUS 2 mg\/g + 10 mg\/g cream\u003c\/u\u003e 1 g of cream contains 2 mg of hyaluronic acid sodium salt and 10 mg of silver sulfadiazine. \u003cu\u003eCONNETTIVINA PLUS 2 mg + 40 mg impregnated gauzes\u003c\/u\u003e Each 10x10 cm gauze is impregnated with 4 g of cream containing 2 mg of hyaluronic acid sodium salt and 40 mg of silver sulfadiazine. \u003cu\u003eCONNETTIVINA PLUS 4 mg + 80 mg impregnated gauzes\u003c\/u\u003e Each 10x20 cm gauze is impregnated with 8 g of cream containing 4 mg of hyaluronic acid sodium salt and 80 mg of silver sulfadiazine. \u003cu\u003eCONNETTIVINA PLUS 12 mg + 240 mg impregnated gauzes\u003c\/u\u003e Each 20x30 cm gauze is impregnated with 24 g of cream containing 12 mg of hyaluronic acid sodium salt and 240 mg of silver sulfadiazine. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003cu\u003eCONNETTIVIN PLUS 2 mg\/g + 10 mg\/g\u003c\/u\u003e \u003cu\u003ecream\u003c\/u\u003e \u003c\/b\u003e Polyethylene glycol 400 monostearate – oleic acid decyl ester – emulsifying wax – glycerol – sorbitol solution 70% – purified water \u003cu\u003eCONNETTIVINA PLUS 2 mg + 40 mg impregnated gauzes\u003c\/u\u003e \u003cu\u003eCONNETTIVINA PLUS 4 mg + 80 mg impregnated gauzes\u003c\/u\u003e \u003cu\u003eCONNETTIVINA PLUS 12 mg + 240 mg impregnated gauzes\u003c\/u\u003e Polyethylene glycol 4000 – glycerol – purified water\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances and other closely chemically related substances or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eCONNETTIVINA PLUS 2 mg\/g + 10 mg\/g cream\u003c\/u\u003e: spread a uniform layer of cream 2–3 mm thick over the entire site of the lesion, once or twice a day. CONNETTIVINA PLUS 2 mg + 40 mg impregnated gauzes \u003cu\u003eCONNETTIVINA PLUS 4 mg + 80 mg impregnated gauzes\u003c\/u\u003e \u003cu\u003eCONNETTIVINA PLUS 12 mg + 240 mg impregnated gauzes\u003c\/u\u003e: Apply one or more medicated gauzes two or more times a day depending on the extent of the lesions. Before applying CONNETTIVINA PLUS, the affected areas must be cleaned preferably with sterile physiological solution (NaCl 0.9%) and disinfected using antiseptics preferably containing povidone iodine or chlorhexidine. If necessary, surgical cleaning must be carried out. In the treatment of burns, cleaning of the lesions is preferable to be carried out only with water or sterile physiological solution, avoiding disinfection with antiseptic agents before applying Connettivina PLUS cream or impregnated gauze. After cleansing the injured parts, spread a uniform layer of cream 2 or 3 mm thick or apply impregnated gauze. The application must continue as long as there is a possibility of infection and until complete healing.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore below 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCONNETTIVINA PLUS must be used with caution in subjects who have shown previous allergies to sulphonamides and in the presence of hepatic or renal insufficiency.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal proteolytic enzymes, applied simultaneously with CONNETTIVINA PLUS, can be inactivated by the presence of silver ions. Do not use simultaneously with disinfectants containing quaternary ammonium salts as hyaluronic acid may precipitate in their presence.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAfter the application of CONNETTIVINA PLUS, local reactions (pain, burning, itching) may occur, even of an allergic nature. Since the systemic administration of sulphonamides can cause adverse reactions such as renal failure, toxic hepatitis, agranulocytosis, thrombocytopenia and leukopenia, it cannot be excluded that the local treatment of large parts of the body with CONNETTIVINA PLUS may give rise to side effects typical of sulphonamides administered systemically\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known cases of overdose.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn the absence of data on the effects of the medicine on the fetus, CONNETTIVINA PLUS must not be used during pregnancy and breastfeeding unless the doctor considers that the therapeutic benefits outweigh the possible risks.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCONNETTIVINA PLUS does not alter the ability to drive or use machinery.\u003c\/p\u003e","brand":"Fidia","offers":[{"title":"Default Title","offer_id":51730206359879,"sku":"028440030","price":13.78,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/fidia-farmaceutici-spa-connettivina-plus-0-2-1-25-g-crema-farmacia-dottor-tili-1213791109.jpg?v=1767139991"},{"product_id":"ortodermina-5-50-g-crema","title":"Ortodermina 5% 50 g cream","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAnesthetic of the accessible mucous membranes of the oro-pharyngeal cavity, anorectal itching. Anesthetic in case of minor skin lesions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of cream contains 6.15 g of Lidocaine hydrochloride, equal to 5 g Lidocaine base. Excipients with known effects: cetostearyl alcohol\u003cb\u003e,\u003c\/b\u003e Methyl p-hydroxybenzoate. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCetostearyl alcohol, Macrogol cetostearyl ether, Vaseline oil, White stringy Vaseline, Methyl p-hydroxybenzoate, Purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eApply the cream on the injured part appropriately; if the skin shows lacerations, it is recommended to spread the cream using a sterile gauze pad. In dentistry, during anesthesia of the mucosa of the oral cavity, dry the latter with a cotton ball and with a saliva ejector in order to minimize the dilution of the cream and promote maximum absorption of the lidocaine. When fitting a new denture, spread the cream on the surface in contact with the mucosa (Important: the settling-in period). In case of anal-rectal itching, to facilitate administration, it is possible to use the applicator cannula (included in the 3 g package). Daily application must not exceed 35 g of cream.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNot necessary.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eORTODERMINA must be used with caution by those subjects who have particularly traumatized mucosa and sepsis in the region intended for application of the cream. In any case, the safety of use depends on the dosage, correct application technique and the adoption of precautionary measures. The product should be used at the minimum effective dose, appropriately reducing the dose in relation to age and physical condition in children, the elderly and acutely ill patients.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known interactions with other substances.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal and general allergic reactions up to anaphylactoid manifestations may occur with the use of lidocaine. The appearance of systemic signs is rare and is due to excessive dosage, rapid absorption, hypersensitivity or reduced tolerance. In these cases, cardiovascular depression and nervous excitation may occur followed by sedation with drowsiness or loss of consciousness. In such cases it is necessary to take appropriate emergency measures. \u003cb\u003eReporting of suspected adverse reactions.\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eExcessive dosage, rapid absorption and hypersensitivity or reduced tolerance cause the appearance of cardiovascular depression and nervous excitation followed by sedation with drowsiness or loss of consciousness. In such cases it is necessary to take appropriate emergency measures.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn pregnant women and in early childhood, the product must be used only in case of actual need and under direct medical supervision.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNot applicable.\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":51730208293191,"sku":"005556016","price":15.72,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-spa-ortodermina-5-50-g-crema-farmacia-dottor-tili-1213791078.jpg?v=1767154290"},{"product_id":"sintotrat-0-5-20-g-crema","title":"Sintotrat 0.5% 20 g cream","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSintotrat 0.5% cream is indicated for the symptomatic treatment of itching, eczema, insect bites, erythema or localized burns.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of cream contains: \u003cstrong\u003eActive ingredient\u003c\/strong\u003e: Hydrocortisone acetate 0.5 g.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePolyglycolic esters of fatty acids, Silicone oil 350 cP, Propylene glycol, Glycerin, Methyl p-hydroxybenzoate, Propyl p-hydroxybenzoate, Ethylenediaminetetraacetic acid, Purified water.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIndividual hypersensitivity confirmed towards the product. As with any other cortisone preparation for topical use, the use of Sintotrat 0.5% cream is contraindicated in the case of viral, bacterial and fungal diseases.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not exceed the recommended doses. If the symptoms do not resolve within a few days, treatment should be discontinued and a doctor should be consulted.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNone\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSintotrat 0.5% cream is indicated for external use only. The cream is not used ophthalmologically, but should be applied to the areas around the eyes. Avoid prolonged applications, particularly on large surfaces. Not to be used in the treatment of vulvar itching if associated with vaginal discharge. \u003cstrong\u003eVisual disturbances\u003c\/strong\u003e Visual disturbances may be reported with the use of systemic and topical corticosteroids. If a patient presents with symptoms such as blurred vision or other visual disturbances, referral to an ophthalmologist should be considered for evaluation of possible causes which may include cataracts, glaucoma, or rare diseases such as central serous chorioretinopathy (CSCR), which have been reported after the use of systemic and topical corticosteroids. In children under two years of age, the product should be administered in cases of real need under the direct supervision of a doctor. Keep the medicine out of the reach of children. Do not use the medicine beyond the expiry date indicated on the package.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo negative interactions or incompatibilities of use with other drugs commonly used in the relevant therapy have ever been identified.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use, especially if prolonged, of products for topical use can give rise to local irritation or sensitization phenomena; in this case it is necessary to interrupt the treatment and consult the doctor in order to institute suitable therapy. Systemic side effects of corticosteroid preparations for topical use are extremely unlikely due to the low doses used; in case of onset it is necessary to interrupt therapy and consult your doctor or pharmacist Classification of expected frequencies: very common (≥1\/10), common (≥1\/100, ≤1\/10), uncommon (≥1\/1000, \u003c1\/100), rare (≥1\/10000, \u003c1\/1000), very rare (\u003c1\/10000), not known (the frequency cannot be defined on the basis of available data). The following adverse reactions have been observed with topical corticosteroids: Eye disorders. Not known: Blurred vision (see also section 4.4). \u003cstrong\u003eReporting of suspected adverse reactions\u003c\/strong\u003e. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCases of overdose are not known with the topical use of hydrocortisone at the concentration contained in Sintotrat 0.5% cream; however, avoid prolonged applications, particularly on large surfaces.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn pregnant women, the product should be administered in cases of actual need under the direct supervision of a doctor.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product does not affect the ability to drive and use machines.\u003c\/p\u003e","brand":"Dompé","offers":[{"title":"Default Title","offer_id":51730209964359,"sku":"025753017","price":11.16,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/dompe-farmaceutici-spa-sintotrat-0-5-20-g-crema-farmacia-dottor-tili-1213791060.jpg?v=1767154649"},{"product_id":"lenirit-0-5-20-g-crema","title":"Lenirit 0.5% 20 g cream","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eInsect bites, itching, localized erythema or burns, eczema.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of cream contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: hydrocortisone acetate 0.5 g. \u003cu\u003eExcipients with known effects\u003c\/u\u003e: methyl parahydroxybenzoate; ethyl parahydroxybenzoate; propyl parahydroxybenzoate. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePolyglycolic ester of C12-C18 fatty acids; self-emulsifying glyceryl monodistearate; squalane; cetyl palmitate; methyl parahydroxybenzoate; ethyl parahydroxybenzoate; propyl parahydroxybenzoate; perfume; purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eKnown hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Infections and skin diseases: tuberculosis, pyoderma, mycosis, as well as skin ulcers and wounds, skin tumors. The use of the cream is contraindicated on the skin of the face, on the anogenital area, on large lesions, infectious diseases (syphilis), viral infectious diseases (such as herpes, chickenpox), perioral dermatitis, acne, acne rosacea, skin reactions after a vaccination, pustular psoriasis. Lenirit should not be used in infants and children under 2 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRubbing lightly, spread the cream on the affected part in a thin layer, twice a day. Do not exceed the recommended doses. LENIRIT must not be used in children under two years of age (see section 4.3).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf conditions worsen or if symptoms persist for more than 7 days, discontinue applications and consult a doctor. Avoid contact with eyes. The use, especially if prolonged, of topical medicines can give rise to irritation or sensitization phenomena. In this case it is necessary to interrupt treatment and institute appropriate therapy. Prolonged use of this medicine may cause telangiectasia and skin atrophy. When used for a long period, or on a large area of ​​skin, hydrocortisone can be absorbed into the blood and exert systemic activity. This eventuality occurs more easily if occlusive dressing is used; the diaper can act as an occlusive bandage. Systemic absorption of topical corticosteroids may result in reversible suppression of the hypothalamic-pituitary-adrenal axis with potential glucocorticosteroid failure after treatment discontinuation. Following the systemic absorption of topical corticosteroids, some patients may also experience manifestations of Cushing's syndrome, glycosuria, hyperglycemia during treatment. Patients who apply a topical steroid to a large surface area or to occlusive areas should be monitored periodically for hypothalamic-pituitary-adrenal axis suppression. Visual disturbances: Visual disturbances may be reported with the use of systemic and topical corticosteroids. If a patient presents with symptoms such as blurred vision or other visual disturbances, referral to an ophthalmologist should be considered for evaluation of possible causes which may include cataracts, glaucoma, or rare diseases such as central serous chorioretinopathy (CSCR), which have been reported after the use of systemic and topical corticosteroids. In case of use in the area adjacent to the eyes, appropriate precautions should be taken. If this happens, the cream residue must be rinsed off with water. The cream contains ethyl parahydroxybenzoate, methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions (even delayed). \u003ci\u003ePediatric population\u003c\/i\u003e: Do not use in infants and children under 2 years of age (see section 4.3). Particular caution is recommended when using the medicine in children due to the risk of systemic exposure to hydrocortisone. Because the body surface area to body weight ratio in children is higher than that in adults, children are at greater risk for systemic corticosteroid effects, including hypothalamic-pituitary-adrenal axis suppression and Cushing's syndrome, than adults. Prolonged use of corticosteroids in children can cause growth and development disorders. The duration of treatment should be as short as possible and the lowest dose should be used. The growth and development of the child should be monitored (see section 4.4). \u003ci\u003eUse in elderly patients\u003c\/i\u003e: Elderly people may experience more marked side effects, especially in cases of co-morbidities, such as osteoporosis, hypertension, hypokalemia, diabetes mellitus, in addition to greater susceptibility to infections and reduction in skin thickness. These people must be carefully monitored to avoid the appearance of life-threatening reactions. In case of subcutaneous atrophic conditions, especially in the elderly, the medicine should be used with caution. \u003ci\u003eUse in patients with renal or hepatic impairment\u003c\/i\u003e: Particular precautions for use must be used in patients with liver disease or renal failure and frequent clinical monitoring of the state of health is necessary.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of interaction and incompatibility with other medicinal products have been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use, especially if prolonged, of products for topical use can give rise to irritation or sensitization phenomena. In this case it is necessary to interrupt treatment and institute appropriate therapy. Acne, steroid-induced purpura, dry skin, hypertrichosis, hypopigmentation of the skin, skin atrophy and striae, telangiectasia, perioral dermatitis, folliculitis, pruritus, blurred vision may occur during application of the cream (see also section 4.4). The greater absorption due to the use of an occlusive bandage can cause systemic effects such as edema, hypertension and compromise of the immune system; suppression of the hypothalamic-pituitary-adrenal axis and Cushing's syndrome may also occur, particularly in pediatric patients. Prolonged use of corticosteroids in children may cause growth and development disorders (see section 4.4). Glaucoma or cataracts may occasionally occur following topical application in the eyelid area (see section 4.4). \u003ci\u003eThe incidence of adverse reactions is not known.\u003c\/i\u003e \u003cb\u003e \u003cu\u003eReporting of suspected adverse reactions.\u003c\/u\u003e \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCases of overdose are not known with the topical use of hydrocortisone at the concentration contained in LENIRIT (0.5%), however prolonged applications should be avoided, particularly on large surfaces. If high doses of the medicinal product are used on large areas of skin, under tight-fitting clothing or on damaged skin, the medicinal product may be absorbed into the blood and cause systemic corticosteroid effects (see section 4.4). In this case, a gradual discontinuation of treatment is recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of Lenirit is not recommended during pregnancy and breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicine does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Eg","offers":[{"title":"Default Title","offer_id":51730209997127,"sku":"025869013","price":12.09,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/eg-spa-lenirit-0-5-20-g-crema-farmacia-dottor-tili-1213791059.jpg?v=1767154630"},{"product_id":"foille-insetti-0-5-15-g-crema","title":"Foille Insetti 0.5% 15 g cream","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eInsect bites, itching, rashes and eczema.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of cream contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: hydrocortisone 0.5 g \u003cu\u003eExcipients with known effects\u003c\/u\u003e: cetyl alcohol, stearyl alcohol, lanolin. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIsopropyl alcohol, cetyl alcohol, stearyl alcohol, lanolin, macrogol 1000 stearate, macrogol 4000 stearate, macrogol 6000 stearate, bitter almond flavoring and purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. The use of hydrocortisone is contraindicated in the case of viral, bacterial and fungal diseases.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRubbing lightly, spread the cream on the affected area in a thin layer, twice a day. Do not exceed the recommended doses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore below 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFOILLE INSETTI must be used only for external use. Do not apply on mucous membranes. Avoid contact with eyes. In children under 2 years of age FOILLE INSETTI must be used only after consulting the doctor and having evaluated with him the risk\/benefit ratio in your case. It is good practice to avoid prolonged use of INSECT FOILS, particularly on large surfaces. The use, especially if prolonged, of products for topical use can give rise to irritation or sensitization phenomena. In this case, it is necessary to stop treatment and consult your doctor in order to institute suitable therapy. If skin irritation appears, treatment must be suspended. After a short period of treatment without appreciable results, consult your doctor. Cases of pheochromocytoma crises, which can be fatal, have occurred after administration of corticosteroids. Corticosteroids should be administered to patients with suspected or proven pheochromocytoma only after an adequate risk\/benefit assessment. \u003cb\u003eVisual disturbances \u003c\/b\u003e Visual disturbances may be reported with the use of systemic and topical corticosteroids. If a patient presents with symptoms such as blurred vision or other visual disturbances, referral to an ophthalmologist should be considered for evaluation of possible causes which may include cataracts, glaucoma, or rare diseases such as central serous chorioretinopathy (CSCR), which have been reported after the use of systemic and topical corticosteroids. Foille Insetti contains cetyl alcohol, stearyl alcohol and lanolin which may cause local skin reactions (e.g. contact dermatitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo notes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAs with all preparations for topical use, local sensitization reactions may occur. Generally speaking, topical application of corticosteroids does not lead to clinical evidence of systemic absorption. When applied to large surfaces, or for prolonged periods of time, or to non-intact skin, or in the case of occlusive dressings, hydrocortisone can be absorbed in quantities sufficient to cause systemic effects. \u003cb\u003e \u003cu\u003eSide effects due to Corticosteroids\u003c\/u\u003e \u003c\/b\u003e The frequency of undesirable effects is classified as follows: very common (≥1\/10); common (≥1\/100, \u003c1\/10); uncommon (≥ 1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000) and not known (frequency cannot be estimated from the available data). \u003cb\u003eEndocrine disorders\u003c\/b\u003e Not known: pheochromocytoma crisis (see section 4.4). \u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e Not known: urticaria. \u003cb\u003eEye pathologies\u003c\/b\u003e Not known: blurred vision, central serous chorioretinopathy (CSCR), (see section 4.4). \u003cb\u003eReporting of suspected adverse reactions \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at http:\/\/www.agenziafarmaco.gov.it\/content\/comesegnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known symptoms that refer to overdose of the drug.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTo be used under the direct supervision of a doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFoille Insetti does not influence the state of vigilance; therefore it does not alter the ability to drive vehicles and use machinery.\u003c\/p\u003e","brand":"Vemedia","offers":[{"title":"Default Title","offer_id":51730211340615,"sku":"020051037","price":10.83,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/vemedia-manufacturing-b-v-foille-insetti-0-5-15-g-crema-farmacia-dottor-tili-1213791029.jpg?v=1767164649"},{"product_id":"sofargen-1-120-g-crema","title":"Sofargen 1% 120g cream","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProphylaxis and local antibacterial treatment of infections in case of 2nd and 3rd degree burns; local antibacterial treatment of varicose ulcers and infected bedsores and in general of dermatological conditions that are infected or susceptible to superinfections.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSOFARGEN 1% cream contains 1 g of micronized silver sulfadiazine. Excipients with known effects: stearyl alcohol, propylene glycol, methyl p-oxybenzoate. For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStearyl alcohol; isopropyl myristate; propylene glycol; polyethylene glycol monostearate; polyoxyethylene sorbitan monolaurate; methyl–p–oxybenzoate; distilled water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients. Since sulphonamides may increase the risk of neonatal jaundice, Sofargen should not be used in women at the end of pregnancy, in premature babies and in newborns in the first months of life.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn burns Sofargen should be applied as early as possible. After a quick cleansing of the injured parts, immediately spread a uniform layer of cream 2 or 3 mm thick on the burnt surfaces. The cream can be applied either directly to the lesions, possibly with the help of a sterile glove, or previously spread on sterile gauze. The application of Sofargen must continue without interruption, once or twice a day, as long as there is a possibility of infection and until complete healing, both in spontaneous and surgical repairs. At each renewal of the dressing, carefully cleanse the wounds with water or physiological solution by showering or sponging. Take care to promptly reapply the cream on surfaces from which it has been inadvertently removed. In other cases, varicose ulcers, bedsores, wounds and dermatological conditions susceptible to infection, cleanse the injured part where necessary and apply a layer of cream 2-3 mm thick, following the same criterion described for the treatment of burns. The lesion must always be kept completely covered by the medicine. If a knee-high type dressing is needed, unwrap 20-30 cm portions of a bandage of adequate length, spread a generous layer of cream, rewrap the impregnated part, unwrap another 20-30 cm and repeat the operation until the entire length of the bandage has been completely impregnated, then apply the required bandage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore at temperatures below 30° C. The product must be used within 6 months of first opening the container.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSofargen should be applied with caution in the presence of hepatic or renal insufficiency. The use of Sofargen may be risky in subjects with manifest glucose-6-phosphate dehydrogenase deficiency, as hemolytic phenomena may occur. Prolonged use of the product may give rise to sensitization phenomena. In this case it is necessary to interrupt the treatment and adopt suitable therapeutic measures. The same applies in case of superinfection by resistant microorganisms. In the treatment of burns of a large part of the body, serum concentrations of sulphonamide can reach therapeutic levels in adults. Therefore, in these patients it would be advisable to monitor these serum levels, renal function, the presence of any sulphonamide crystals in the urine and liver function, interrupting therapy if liver and\/or renal function is compromised. Furthermore, given that propylene glycol, present as an excipient in the composition, can cause hyperosmolality when the product is applied to large burn areas, serum osmolality must be periodically checked and, if necessary, the treatment must be interrupted.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal proteolytic enzymes, applied simultaneously with Sofargen, can be inactivated by the presence of silver ions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSome cases of transient leukopenia (0.4%), rare local disorders (pain and burning) and rare local allergic reactions (0.3%) have been reported. The classic side effects of systemically administered sulphonamides cannot be excluded when treating large parts of the body. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo symptoms of overdose have been highlighted in the literature.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince there is no exhaustive experimental data on the possible effects of the drug on the fetus, Sofargen should not be used during pregnancy and breastfeeding unless, in the opinion of the doctor, its use is indispensable and essential for the pregnant woman (see 4.3).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSofargen does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":51730211373383,"sku":"025561073","price":24.83,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-spa-sofargen-1-120-g-crema-farmacia-dottor-tili-1213791028.jpg?v=1767164747"},{"product_id":"sofargen-1-30-g-crema","title":"Sofargen 1% 30g cream","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProphylaxis and local antibacterial treatment of infections in case of 2nd and 3rd degree burns; local antibacterial treatment of varicose ulcers and infected bedsores and in general of dermatological conditions that are infected or susceptible to superinfections.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSOFARGEN 1% cream contains 1 g of micronized silver sulfadiazine. Excipients with known effects: stearyl alcohol, propylene glycol, methyl p-oxybenzoate. For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStearyl alcohol; isopropyl myristate; propylene glycol; polyethylene glycol monostearate; polyoxyethylene sorbitan monolaurate; methyl–p–oxybenzoate; distilled water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients. Since sulphonamides may increase the risk of neonatal jaundice, Sofargen should not be used in women at the end of pregnancy, in premature babies and in newborns in the first months of life.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn burns Sofargen should be applied as early as possible. After a quick cleansing of the injured parts, immediately spread a uniform layer of cream 2 or 3 mm thick on the burnt surfaces. The cream can be applied either directly to the lesions, possibly with the help of a sterile glove, or previously spread on sterile gauze. The application of Sofargen must continue without interruption, once or twice a day, as long as there is a possibility of infection and until complete healing, both in spontaneous and surgical repairs. At each renewal of the dressing, carefully cleanse the wounds with water or physiological solution by showering or sponging. Take care to promptly reapply the cream on surfaces from which it has been inadvertently removed. In other cases, varicose ulcers, bedsores, wounds and dermatological conditions susceptible to infection, cleanse the injured part where necessary and apply a layer of cream 2-3 mm thick, following the same criterion described for the treatment of burns. The lesion must always be kept completely covered by the medicine. If a knee-high type dressing is needed, unwrap 20-30 cm portions of a bandage of adequate length, spread a generous layer of cream, rewrap the impregnated part, unwrap another 20-30 cm and repeat the operation until the entire length of the bandage has been completely impregnated, then apply the required bandage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore at temperatures below 30° C. The product must be used within 6 months of first opening the container.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSofargen should be applied with caution in the presence of hepatic or renal insufficiency. The use of Sofargen may be risky in subjects with manifest glucose-6-phosphate dehydrogenase deficiency, as hemolytic phenomena may occur. Prolonged use of the product may give rise to sensitization phenomena. In this case it is necessary to interrupt the treatment and adopt suitable therapeutic measures. The same applies in case of superinfection by resistant microorganisms. In the treatment of burns of a large part of the body, serum concentrations of sulphonamide can reach therapeutic levels in adults. Therefore, in these patients it would be advisable to monitor these serum levels, renal function, the presence of any sulphonamide crystals in the urine and liver function, interrupting therapy if liver and\/or renal function is compromised. Furthermore, given that propylene glycol, present as an excipient in the composition, can cause hyperosmolality when the product is applied to large burn areas, serum osmolality must be periodically checked and, if necessary, the treatment must be interrupted.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal proteolytic enzymes, applied simultaneously with Sofargen, can be inactivated by the presence of silver ions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSome cases of transient leukopenia (0.4%), rare local disorders (pain and burning) and rare local allergic reactions (0.3%) have been reported. The classic side effects of systemically administered sulphonamides cannot be excluded when treating large parts of the body. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo symptoms of overdose have been highlighted in the literature.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince there is no exhaustive experimental data on the possible effects of the drug on the fetus, Sofargen should not be used during pregnancy and breastfeeding unless, in the opinion of the doctor, its use is indispensable and essential for the pregnant woman (see 4.3).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSofargen does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":51730211701063,"sku":"025561010","price":13.67,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-spa-sofargen-1-30-g-crema-farmacia-dottor-tili-1213791018.jpg?v=1767164908"},{"product_id":"acido-salicilico-marco-viti-10-30-g-unguento","title":"Salicylic acid Marco Viti 10% 30 g ointment","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e– Treatment of psoriasis, acne vulgaris, seborrhea in adults and children; – Removal of warts and calluses in adults and children; – Local treatment of some forms of eczema and ichthyosis in adults.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSalicylic acid Marco Viti 2% ointment 100 g of ointment contain \u003ci\u003eActive ingredient\u003c\/i\u003e: salicylic acid 2 g. Salicylic acid Marco Viti 5% ointment 100 g of ointment contain \u003ci\u003eActive ingredient\u003c\/i\u003e: salicylic acid 5 g. Salicylic acid Marco Viti 10% ointment 100 g of ointment contain \u003ci\u003eActive ingredient\u003c\/i\u003e: salicylic acid 10 g. For the complete list of excipients see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWhite Vaseline.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e– hypersensitivity to the active ingredient, to salicylates or to any of the excipients (patients hypersensitive to salicylates, such as acetylsalicylic acid, propylsalicylate, bromosacylic acid, zinc salicylate, may also be hypersensitive to salicylic acid); – children under the age of 2; – diabetes (see section 4.8); – peripheral vascular disease.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eApply locally the minimum quantity of ointment in relation to the area to be treated with a light massage. Begin treatment by applying the medicine only to a small portion of the skin or only once a day, so as not to irritate the skin.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore in a tightly closed container, protected from light.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicine must not be swallowed. Salicylic acid is irritating and could cause dermatitis (see section 4.8); When treating calluses and warts, it is necessary to protect the surrounding intact skin to minimize the absorption of the active ingredient. Salicylic acid must not be used for long periods of time, at high concentrations, on large areas of the body, or on damaged or inflamed skin, as excessive absorption of the active ingredient can cause systemic salicylate poisoning (see section 4.9) mainly in children, which can be fatal. Avoid contact with mouth, eyes, genitals and other mucous membranes. Use with caution in children as experience on the use of salicylic acid in this population is limited. It is possible to observe an improvement in the treated skin after 6 weeks of therapy or after 12 weeks in the case of removal of a wart.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSalicylic acid may interact with the following medicines: – Coumarin anticoagulants (acenocoumarol, dicoumarol, phenprocumon and warfarin) and 1,3-idandione derivatives (anisindione, phenidione), as salicylic acid can inhibit platelet aggregation and displace them from their binding site with plasma proteins, thus causing an increased risk of bleeding. – Inhibitors of coagulation-activated factor – Glyburide, since, due to an unknown mechanism, excessive hypoglycemia could occur. – Probenecid, as salicylic acid can cause the reversal of the uricosuric effects of this drug. – Acetazolamide, as you may experience an increase in side effects of salicylate. – Chickenpox vaccine, as salicylic acid may cause an increased risk of developing Reye's syndrome. Furthermore, salicylic acid should not be used at the same time as tamarind (tropical tree belonging to the \u003ci\u003eFabaceae\u003c\/i\u003e) and Salvia miltiorrhiza or Tan–Shen (plant of the \u003ci\u003eLabiateae\u003c\/i\u003e), as there could be a rapid increase in plasma levels of salicylate with consequent increase in toxicity.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBelow are the side effects of salicylic acid, organized according to the MedDRA systemic classification. There is insufficient data to establish the frequency of the individual effects listed. \u003ci\u003eMetabolism and nutrition disorders\u003c\/i\u003e Hypoglycemia. \u003ci\u003ePathologies of the skin and subcutaneous tissue\u003c\/i\u003e Irritations, dermatitis, burning, itching, erythema, peeling of the skin, scars on the face.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose with topically applied salicylic acid have been reported. However, in case of excessive absorption of the active ingredient (e.g. prolonged application on large areas of the body or on damaged and inflamed skin) a state of salicylism could occur. The symptoms of salicylism are: nausea, vomiting, tinnitus (or tinnitus) and dizziness. Rarely, the following may occur: gastric ulcer, asthma, hepatotoxicity, renal failure and pancreatic toxicity.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no adequate data regarding the use of salicylic acid in pregnant and breastfeeding women. Therefore, salicylic acid solutions and ointments should not be used during pregnancy and breastfeeding unless absolutely necessary. Studies conducted on animals have shown reproductive toxicity (see section 5.3). While the potential risk for humans is unknown. However, it should be considered that despite being used topically, salicylic acid is absorbed systemically, easily crosses the placenta, finding itself in higher concentrations in fetal plasma and is excreted in breast milk (see section 5.2).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSalicylic acid does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Marco Viti","offers":[{"title":"Default Title","offer_id":51730211766599,"sku":"030354031","price":5.12,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/marco-viti-farmaceutici-spa-acido-salicilico-marco-viti-10-30-g-unguento-farmacia-dottor-tili-1213791017.jpg?v=1767164889"},{"product_id":"vectavir-labiale-1-2-g-crema","title":"Vectavir labial 1% 2 g cream","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVECTAVIR LABIALE is indicated for the treatment of herpes labialis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach gram of cream contains 10 mg of penciclovir. Excipients with known effects: 77.2 mg of cetostearyl alcohol, 416 mg of propylene glycol. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSolid paraffin Liquid paraffin Cetostearyl alcohol Propylene glycol Cetomacrogol 1000 Red iron oxide (E-172) Yellow iron oxide (E-172) Purified water\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance, to famciclovir or to any of the excipients listed in section 6.1. Children under the age of 12.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003ci\u003eAdults (including the elderly) and children over 12 years of age\u003c\/i\u003e \u003c\/b\u003e VECTAVIR LABIALE should be applied at intervals of approximately 2 hours throughout the day. Treatment, to be continued for 4 days, should be started as soon as possible, at the first sign of infection. However, even in patients who start therapy later, VECTAVIR LABIALE has proven effective in accelerating the healing of lesions, reducing the pain associated with them and shortening the time for viral spread. \u003cb\u003e \u003ci\u003ePediatric population Children (under 12 years of age) \u003c\/i\u003e \u003c\/b\u003e The use of VECTAVIR LABIALE is not recommended in children under 12 years of age due to a lack of data on safety and\/or efficacy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not freeze. Do not store the medicine packaged in the 2 g aluminum tube at temperatures above 25°C. Do not store medicines packaged in the 2 g plastic bottle with dispenser and the 5 g aluminum tube at temperatures above 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe cream should only be applied to lesions on the lips and around the mouth. It is not recommended for application on mucous membranes (e.g. in the eyes, mouth or nose or on the genitals). Particular care should be taken to avoid application in or near the eyes. Severely immunocompromised patients (e.g. patients with AIDS or bone marrow transplant recipients) should be encouraged to consult a physician if oral therapy is indicated. VECTAVIR LABIALE contains cetostearyl alcohol: it may cause local skin reactions (e.g. contact dermatitis). VECTAVIR LABIALE contains 416 mg of propylene glycol in each gram of cream: it may cause skin irritation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eExperience in clinical trials has not identified interactions resulting from the concomitant administration of drugs for topical or systemic use and VECTAVIR LABIALE cream.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVECTAVIR LABIALE cream was well tolerated during studies in humans. Experience from clinical trials has shown that there is no difference in the frequency or type of adverse reactions between VECTAVIR LABIALE cream and placebo. The most common events are adverse events in the application area. Adverse reactions are listed below by system organ class, class and frequency. The frequencies are defined as follows: \u003ci\u003eVery common\u003c\/i\u003e (\u0026gt;1\/10); \u003ci\u003ecommon\u003c\/i\u003e (\u003e1\/100 to \u003c1\/10); \u003ci\u003euncommon\u003c\/i\u003e (\u003e1\/1,000 to \u003c1\/100); \u003ci\u003erare\u003c\/i\u003e (\u003e1\/10,000 to \u003c1\/1,000); \u003ci\u003every rare\u003c\/i\u003e (\u0026lt;1\/10.000), \u003ci\u003enot known\u003c\/i\u003e (frequency cannot be estimated from the available data). Within each frequency class, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003eGeneral pathologies and disorders at the application site.\u003c\/p\u003e\n\u003cp\u003eCommon: Application site reactions (including skin burning sensation, skin pain, hypoesthesia).\u003c\/p\u003e\n\u003cp\u003ePost-marketing surveillance highlighted the following adverse events (all reactions were either localized or general). It is difficult to define a frequency for post-marketing adverse events and therefore events are listed with an unknown frequency\u003c\/p\u003e\n\u003cp\u003eImmune system disorders: Hypersensitivity, urticaria.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders: Allergic dermatitis (including rash, pruritus, blisters and edema).\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eReporting of suspected adverse reactions \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEven after oral ingestion of the entire contents of a pack of VECTAVIR LABIALE cream, no side effects should occur; penciclovir is poorly absorbed after oral administration. However, irritation of the oral cavity may occur. In case of accidental ingestion, no specific treatment is necessary.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e When the cream is used in pregnant women, there is unlikely to be any cause for concern about adverse effects as the systemic absorption of penciclovir following topical application of VECTAVIR LABIALE cream was found to be minimal (see Section 5.2). As the safety of penciclovir in pregnant women has not been established, VECTAVIR LABIALE cream should be used on the advice of a doctor during pregnancy or by mothers who are breastfeeding, only if the potential benefits outweigh the potential risks associated with treatment. \u003cb\u003eBreastfeeding\u003c\/b\u003e When the cream is used in women who are breastfeeding, there is unlikely to be any cause for concern about adverse effects as systemic absorption of penciclovir following topical application of VECTAVIR LABIALE cream has been found to be minimal (see Section 5.2). There is no information on the excretion of penciclovir in human milk.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVectavir Labiale does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Perrigo","offers":[{"title":"Default Title","offer_id":51730213241159,"sku":"032154015","price":13.48,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/perrigo-italia-srl-vectavir-labiale-1-2-g-crema-farmacia-dottor-tili-1213791003.jpg?v=1767155970"},{"product_id":"zinco-ossido-marco-viti-10-30-g-unguento","title":"Zinc oxide Marco Viti 10% 30 g ointment","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSoothing and protective treatment of eczema, dermatosis and minor abrasions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of ointment contain Active ingredient: zinc oxide 10.0 g. For full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWhite Vaseline, liquid paraffin.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eApply the ointment locally, 1 or 2 times a day, on appropriately washed and dried skin. Due to its astringent and decongestant action it can also be used on irritated skin (for example diaper rash). Apply a layer of ointment to cover the affected area (especially when used to treat diaper rash); in case of burns and non-infected skin lesions, it is preferable to apply a thin layer of ointment, using a bandage if necessary. Perform a light circular massage on the affected area, so as to obtain partial absorption of the ointment, following which an opaque white residue remains.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore in the original container protected from light.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicine must be used for external use only; may be harmful if ingested (see paragraph 4.9). Avoid contact of the drug with the eyes; in case of accidental contact, wash thoroughly with water. Do not use the medicine in case of burns or potentially infected wounds. If the ointment is used for diaper rash, watch for the rash to improve within a few days; otherwise, you need to resort to a different treatment. The use, especially if prolonged, of medicines for local use can give rise to irritation or sensitization phenomena. In this case, it is necessary to interrupt treatment and institute appropriate therapy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo notes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBelow are the side effects of zinc oxide organized according to the MedDRA system organic classification. There is insufficient data to establish the frequency of the individual effects listed. \u003ci\u003eImmune system disorders\u003c\/i\u003e Allergic\/hypersensitivity reaction: rash, hives, itching and\/or swelling (especially of the face, tongue, throat, lips), tightness in the chest, difficulty breathing.\u003ci\u003ePathologies of the skin and subcutaneous tissue\u003c\/i\u003e Skin irritation. Burning, tingling and dark spots on the skin.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported. The poor percutaneous absorption of the drug makes the occurrence of symptoms and signs of overdose unlikely. In case of accidental ingestion, the following symptoms may be seen: diarrhoea, nausea and vomiting, hypoglycaemia, confusion, fatigue, lethargy, bleeding, jaundice, dark urine, cough, chills and fever, oral cavity irritation, kidney problems, copper deficiency.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGenerally, the use of the ointment during pregnancy and breastfeeding is considered safe if applied to limited areas and for short periods of time. \u003ci\u003ePregnancy\u003c\/i\u003e For zinc oxide ointment no clinical data on exposed pregnancies are available. This medicine, if used in accordance with the instructions for use, is not absorbed and therefore does not cause systemic effects; in case of damaged skin, it can be absorbed in minimal quantities. \u003ci\u003eBreastfeeding\u003c\/i\u003e There are no data available on the use of the medicine during breastfeeding and it is not known whether this active ingredient passes into breast milk. However, since the absorption of the drug can be considered negligible, it is very unlikely that significant quantities reach the breast milk.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicine does not alter the ability to drive or use machines.\u003c\/p\u003e","brand":"Marco Viti","offers":[{"title":"Default Title","offer_id":51730213503303,"sku":"030360010","price":5.39,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/marco-viti-farmaceutici-spa-zinco-ossido-marco-viti-10-30-g-unguento-farmacia-dottor-tili-1213791000.jpg?v=1767156027"},{"product_id":"ictammolo-marco-viti-10-50-g-unguento","title":"Ictammol Marco Viti 10% 50 g ointment","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eInflammations and small skin infections. Furunculosis (pimples), abscesses and superficial skin ulcerations. Inflammation of the sweat glands (hidradenitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of ointment contain Active ingredient: ammonium sulfoicthiolate 10 g. \u003ci\u003eFor the full list of excipients, see section 6.1.\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWhite Vaseline.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eApply the ointment, in the quantity necessary in relation to the part to be treated, 2-3 times a day, covering with gauze.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore the container tightly closed in the original packaging protected from light.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not apply near the eyes and on the mucous membranes. Avoid exposure to the sun and UVA rays after application. The use, especially if prolonged, of medicines for local use can give rise to irritation or sensitization phenomena. If this occurs, discontinue treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo specific interaction studies have been performed.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBelow are the side effects of Ictammol, organized according to the MedDRA system organ classification. There is insufficient data to establish the frequency of the individual effects listed. \u003ci\u003ePathologies of the skin and subcutaneous tissue\u003c\/i\u003e Dermatitis, burning, skin irritation, hypersensitivity reactions\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf used in excessive quantities it can be irritating to the skin and mucous membranes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn the absence of specific studies, the medicine should be used during pregnancy and breastfeeding only if necessary and under direct medical supervision.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicine does not alter the ability to drive or use machines.\u003c\/p\u003e","brand":"Marco Viti","offers":[{"title":"Default Title","offer_id":51730213536071,"sku":"030338026","price":5.39,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/marco-viti-farmaceutici-spa-ictammolo-marco-viti-10-50-g-unguento-farmacia-dottor-tili-1213790999.jpg?v=1767156009"},{"product_id":"fenistil-0-1-30-g-gel","title":"Fenistil 0.1% 30 g gel","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal symptomatic treatment of itchy dermatitis, solar erythema, insect bites.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne gram of gel contains dimethindene maleate 1 mg Excipients with known effects: propylene glycol, benzalkonium chloride. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenzalkonium chloride; sodium edetate; carbomer; sodium hydroxide; propylene glycol; purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Do not use with occlusive dressings.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eApply the gel on the affected part with a light massage, to favor its deep penetration, 2-3 times a day, depending on the intensity of the inflammatory symptom. Do not exceed the recommended doses. Use only for short periods of time (no longer than 5-7 days).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore below 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use, especially if prolonged, of products for topical use can give rise to sensitization phenomena; if this occurs, treatment should be suspended and appropriate therapy instituted. Avoid applying the product when the skin has very extensive abrasions, to avoid systemic absorption of the product; also do not apply it on areas of skin with blisters, on live sores or on exuding surfaces. Avoid contact of the preparation with the eyes and prolonged exposure to the sun of the treated areas. \u003cu\u003ePediatric population\u003c\/u\u003e In children under 2 years of age, the use of the preparation on large skin surfaces, particularly on abraded and inflamed areas, should be avoided. \u003cu\u003eInformation on excipients\u003c\/u\u003e Fenistil gel contains 300 mg of propylene glycol per dose (2 g of gel) equivalent to 150 mg\/g of gel which may cause skin irritation. Fenistil gel also contains 0.1 mg of benzalkonium chloride per dose (2 g of gel) equivalent to 0.05 mg\/g of gel which may irritate the skin. If you are breastfeeding, do not apply this medicine to your breasts because your baby may ingest it with his milk.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo interaction studies have been performed; however, the absorption of the active ingredient contained in Fenistil 0.1% gel in the body is very low and therefore interactions are very unlikely.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSafety profile summary\u003c\/b\u003e The most commonly reported adverse reactions during treatment are mild and transient skin reactions at the application site. \u003cb\u003eTable of adverse reactions\u003c\/b\u003e Adverse reactions are listed below, by system organ class and frequency. Within each frequency class, undesirable effects are presented in order of decreasing seriousness. Frequency categories for each adverse reaction include: very common (≥1\/10); common (≥1\/100, \u003c1\/10); uncommon (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known (frequency cannot be estimated from the available data). \u003ci\u003e \u003cu\u003ePathologies of the skin and subcutaneous tissue.\u003c\/u\u003e \u003c\/i\u003eUncommon: dry skin, burning sensation on the skin; Very rare (based on post-marketing reports): allergic dermatitis; Frequency not known: allergic skin reactions. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSymptoms\u003c\/b\u003e So far, no case of overdose with Fenistil gel has been reported. However, accidental ingestion of considerable quantities of Fenistil gel may induce some symptoms characteristic of overdose with type H antihistamines\u003csub\u003e1\u003c\/sub\u003e: CNS depression with drowsiness (especially in adults), CNS stimulation and anticholinergic effects (especially in children and the elderly), including excitement, ataxia, hallucinations, tonic-clonic spasms, mydriasis, dry mouth, facial flushing, urinary retention and fever. Hypotension may also occur. \u003cb\u003eManagement\u003c\/b\u003e There is no specific antidote in case of overdose of antihistamines. The usual emergency measures must be implemented which include, in case of ingestion: activated charcoal, saline laxatives and, if necessary, the usual cardiorespiratory support measures. No stimulants should be administered; vasopressor drugs may be used to treat hypotension.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e No clinical data on pregnancy are available for dimethindene maleate. Animal studies have not shown any direct or indirect harmful effects on pregnancy or the fetus\/newborn. Fenistil gel should be used during pregnancy only after the doctor has assessed the risk\/benefit ratio in favor of the latter. During pregnancy, Fenistil gel should not be applied to large skin surfaces, especially if abraded or inflamed. \u003cb\u003eBreastfeeding\u003c\/b\u003e Fenistil gel should be used during breastfeeding only after the doctor has assessed the risk\/benefit ratio in favor of the latter. During breastfeeding, Fenistil gel should not be applied to large skin surfaces, especially if abraded or inflamed. However, the product should not be applied to the breasts during breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFenistil gel has no or negligible influence on the ability to drive and use machinery.\u003c\/p\u003e","brand":"Haleon","offers":[{"title":"Default Title","offer_id":51730213667143,"sku":"020124121","price":11.64,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/haleon-italy-srl-fenistil-0-1-30-g-gel-farmacia-dottor-tili-1213790996.jpg?v=1767156069"},{"product_id":"aciclovir-mylan-generics-5-3-g-crema","title":"Aciclovir Mylan Generics 5% 3 g cream","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAciclovir Mylan Generics cream is indicated in the treatment of Herpes simplex skin infections such as: primary or recurrent genital herpes and herpes labialis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne gram of cream contains 50 mg of acyclovir. Excipient with known effects: methyl parahydroxybenzoate. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTefose 1500, glycerol, stearic acid, liquid paraffin, methyl parahydroxybenzoate, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance, to valaciclovir or to any of the excipients listed in section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDosage Aciclovir cream must be applied 5 times a day at intervals of approximately 4 hours. Aciclovir cream should be applied to lesions or areas where infections are developing as soon as possible after the infection has started. It is particularly important to begin treatment of recurrent episodes during the prodrome phase or at the first appearance of lesions. Treatment can also be started during the later stages (papules or vesicles). Treatment must continue for at least 4 days for herpes labialis and for 5 days for genital herpes. If there is no healing, treatment can continue for up to a maximum of 10 days.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore at a temperature not exceeding 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAciclovir cream is not recommended for application to mucous membranes, such as those of the mouth, eyes or vagina, as it may be irritating. Particular care must be taken to avoid accidental introduction into the eyes. Animal studies indicate that application of aciclovir cream into the vagina may cause reversible irritation. In severely immunocompromised patients (e.g. AIDS patients or bone marrow transplant patients), oral administration of acyclovir should be considered. Such patients should be advised to consult their doctor regarding the treatment of any infection. The use of the product, especially if prolonged, can give rise to sensitization phenomena, where this occurs it is necessary to interrupt the treatment and consult the doctor. No phenomena of addiction or dependence on the drug have been reported. Contains methyl parahydroxybenzoate, which may cause allergic reactions (even delayed).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo clinically significant interactions have been identified.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following convention was used for the classification of undesirable effects in terms of frequency: very common ≥1\/10, common ≥1\/100 and \u003c1\/10, uncommon 1\/1000 and \u003c1\/100, rare ≥1\/10,000 and \u003c1\/1000, very rare \u003c1\/10,000. Data from clinical trials were used to assign frequency categories to adverse reactions observed during clinical trials with aciclovir 3% ophthalmic ointment. Due to the nature of the adverse events observed, it is not possible to unambiguously determine which events are related to the administration of the drug and which are related to the disease itself. Data from spontaneous reports were used as a basis to determine the frequency of those events observed post-marketing. \u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e Uncommon: Transient burning or pain after application of aciclovir cream Moderate dryness or peeling of the skin Itching Rare: Erythema. Contact dermatitis following application. Where sensitivity tests were conducted, it was shown that the substances causing reactivity phenomena were the components of the base cream rather than acyclovir. \u003cb\u003eImmune system disorders\u003c\/b\u003e Very rare: Immediate hypersensitivity reactions including angioedema and urticaria \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reaction via the national reporting system to the Italian Medicines Agency, Website: http:\/\/www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEven if the entire contents of a tube of cream containing 500 mg of aciclovir is ingested, no side effects should occur.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePregnancy The use of aciclovir cream should be considered only when the potential benefits outweigh the possibility of unknown risks. However, systemic exposure following topical application of aciclovir cream is very low. A registry on the use of aciclovir in pregnancy provided data on pregnancy outcomes in women exposed to various post-marketing formulations of aciclovir. These observations did not show an increase in the number of birth anomalies among subjects exposed to aciclovir compared to the general population. All defects found at birth did not show any unique or consistent characteristics that would suggest a common cause. Systemic administration of aciclovir, in internationally accepted conventional tests, did not produce embryotoxic or teratogenic effects in rabbits, rats or mice. In an experimental test not included in standard teratogenicity tests, in rats, fetal abnormalities were observed after subcutaneous doses of acyclovir so high as to produce toxic effects on the mother. The clinical relevance of these findings is uncertain. Breastfeeding Limited data in humans indicate that aciclovir is found in breast milk after systemic administration. However, the dose received by an infant following use of aciclovir cream by the mother should be insignificant. Fertility See clinical studies in paragraphs 5.2 and 5.3.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known negative effects of aciclovir cream on the ability to drive and use machines.\u003c\/p\u003e","brand":"Mylan","offers":[{"title":"Default Title","offer_id":51730213830983,"sku":"034738017","price":8.65,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/mylan-spa-aciclovir-mylan-generics-5-3-g-crema-farmacia-dottor-tili-1213791353.jpg?v=1767156207"},{"product_id":"aciclovir-eg-5-3-g-crema","title":"Aciclovir EG 5% 3 g cream","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eACICLOVIR EG cream is indicated in the treatment of Herpes Simplex skin infections such as: primary or recurrent genital herpes and Herpes labialis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003e1 g of cream contains\u003c\/u\u003e: \u003ci\u003eActive ingredient:\u003c\/i\u003e acyclovir: 50 mg. Excipients with known effects: 67.5 mg of cetostearyl alcohol, 7.5 mg of sodium lauryl sulfate, 200 mg of propylene glycol (E1520). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePoloxamer 407; Cetostearyl alcohol; Sodium lauryl sulfate; White Vaseline; Liquid paraffin; Sucrose monopalmitate; Propylene glycol (E1520); Purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eACICLOVIR EG cream is contraindicated in patients with known hypersensitivity to aciclovir, valaciclovir, propylene glycol or any of the excipients listed in section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eACICLOVIR EG CREMA must be applied 5 times a day at intervals of approximately 4 hours. ACICLOVIR EG cream must be applied to the lesions, or to the areas where they are developing, as soon as possible, preferably during the earliest stages (prodromes or erythema). Treatment can also be started during the later stages (papules or vesicles). Treatment must continue for at least 4 days for herpes labialis and for 5 days for genital herpes. If there is no healing, treatment can continue for up to a maximum of 10 days.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore at a temperature not exceeding 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAciclovir cream is not recommended for ophthalmic use, nor is application to the mucous membranes of the mouth or vagina as it may be irritating. Particular care should be taken to avoid accidental application into the eyes. Animal studies indicate that the application of ACICLOVIR EG cream into the vagina may cause reversible irritation. In severely immunocompromised patients (patients with AIDS or patients with bone marrow transplant) the administration of acyclovir in oral formulations should be considered. It should be recommended that such patients consult their doctor regarding the treatment of any infection. The use of the product, especially if prolonged, can give rise to sensitization phenomena, if this happens it is necessary to interrupt the treatment and consult the doctor. No phenomena of addiction or dependence on the drug have been reported. \u003ci\u003eImportant information about some excipients\u003c\/i\u003e This medicine contains cetostearyl alcohol which may cause localized skin reactions (e.g. contact dermatitis). This medicine contains 7.5 mg of sodium lauryl sulphate per g of cream. Sodium lauryl sulfate may cause skin irritation (stinging or burning sensation) or intensify skin reactions caused by other medicines when applied to the same area. This medicine contains 200 mg of propylene glycol per g of cream.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo clinically significant interactions have been identified.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following convention was used for the classification of side effects in terms of frequency: very common ≥ 1\/10, common ≥ 1\/100 and \u003c 1\/10, uncommon ≥ 1\/1,000 and \u003c 1\/100, rare ≥ 1\/10,000 and \u003c 1\/1,000, very rare \u003c 1\/10,000. To assign frequency categories to the adverse reactions observed during clinical studies on the use of aciclovir cream, data from these clinical studies were used. Due to the nature of the adverse events observed, it is not possible to unambiguously determine which events are related to the administration of the drug and which are related to the disease itself. Data from spontaneous reports were used as a basis to determine the frequency of those events detected by post-marketing pharmacovigilance. \u003cb\u003ePathologies of the skin and subcutaneous tissue.\u003c\/b\u003e Uncommon: Transient burning or pain after application of aciclovir cream. Moderate dryness and flaking of the skin. Itching. Rare: Erythema. Contact dermatitis after application. Where sensitivity tests had been conducted, it was demonstrated that the substances causing reactivity phenomena were the components of the base cream rather than aciclovir. \u003cb\u003eImmune system disorders.\u003c\/b\u003e Very rare: immediate hypersensitivity reactions including angioedema and urticaria. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEven if the entire contents of a 10 g tube of cream containing 500 mg of acyclovir are swallowed, no undesirable effects should be expected.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFertility See \u003ci\u003eClinical studies\u003c\/i\u003e in paragraph 5.2. Pregnancy The use of aciclovir should only be considered if the potential benefits outweigh the possibility of unknown risks, however, the systemic exposure to aciclovir following topical application of aciclovir cream is very low. A post-marketing registry on the use of aciclovir in pregnancy provided data on pregnancy outcomes in women exposed to various formulations of aciclovir. These observations did not show an increase in the number of birth defects among subjects exposed to aciclovir compared to the general population and all birth defects did not show any particularity or common characteristics, such as to suggest a single cause. Systemic administration of aciclovir in internationally accepted standard tests did not produce embryonic toxicity or teratogenic effects in rabbits, rats or mice. In an experimental test in rats not included in the classic teratogenesis tests, fetal anomalies were observed after subcutaneous doses of acyclovir so high as to produce toxic effects in the mother. However, the clinical relevance of these findings is uncertain. Breastfeeding Limited data indicate that the drug is found in breast milk following systemic administration. However, the dose received by an infant following the use of aciclovir cream by the mother should be insignificant.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNone known.\u003c\/p\u003e","brand":"Eg","offers":[{"title":"Default Title","offer_id":51730213863751,"sku":"032307047","price":7.44,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/eg-spa-aciclovir-eg-5-3-g-crema-farmacia-dottor-tili-1213791352.jpg?v=1767156189"}],"url":"https:\/\/www.dottortili.com\/en\/collections\/farmaci-dermatologici-creme-pomate-e-unguenti.oembed?page=2","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}